<?xml version="1.0" encoding="UTF-8"?>
<!-- generator="wordpress/2.2.1" -->
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	>

<channel>
	<title>SocietyofCollegeMedicine.com</title>
	<link>http://societyofcollegemedicine.com</link>
	<description>We provide patients and family members a FREE, fast, simple and central location so you can make GOOD medical decisions!</description>
	<pubDate>Wed, 16 May 2012 19:49:44 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.2.1</generator>
	<language>en</language>
			<item>
		<title>Clinical news we are currently tracking&#8230;</title>
		<link>http://societyofcollegemedicine.com/2012/05/16/clinical-news-we-are-currently-tracking-4/</link>
		<comments>http://societyofcollegemedicine.com/2012/05/16/clinical-news-we-are-currently-tracking-4/#comments</comments>
		<pubDate>Wed, 16 May 2012 19:49:44 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://societyofcollegemedicine.com/2012/05/16/clinical-news-we-are-currently-tracking-4/</guid>
		<description><![CDATA[




News
10 new results for clinical trial








Clinical Trials Hope To Help Fight, Prevent Alzheimer&#8217;s
NewsChannel5.com
In a highly unusual move, researchers will focus this clinical trial  on patients near Medellin, Colombia. Hundreds of people in one extended  family were born with the genetic flaw that makes it certain they will  contract Alzheimer&#8217;s by the age [...]]]></description>
			<content:encoded><![CDATA[<table width="600px" border="0" cellpadding="0" cellspacing="0">
<tr>
<td style="background-color: #ebeff9; padding: 4px 8px">
<table width="100%" border="0" cellpadding="0" cellspacing="0">
<tr>
<td><font size="-1"><strong>News</strong></font></td>
<td align="right" width="70%"><font size="-1"><strong>10</strong> new results for <strong>clinical trial</strong></font></td>
</tr>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.newschannel5.com/story/18434286/clinical-trials-hope-to-help-fight-prevent-alzheimers&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAAOABA54vP_QRIAVAAWABiBWVuLVVT&amp;cd=_C-NGkCQqQA&amp;usg=AFQjCNGYzMEyKS-UuQk8TUusBIBpDC8PgA" style="color: #1111cc" target="_blank"><strong>Clinical Trials</strong> Hope To Help Fight, Prevent Alzheimer&#8217;s</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">NewsChannel5.com</a><br />
In a highly unusual move, researchers will focus this <strong>clinical trial</strong>  on patients near Medellin, Colombia. Hundreds of people in one extended  family were born with the genetic flaw that makes it certain they will  contract Alzheimer&#8217;s by the age of 50.<br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.newschannel5.com/story/18434286/clinical-trials-hope-to-help-fight-prevent-alzheimers%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAAOABA54vP_QRIAVAAWABiBWVuLVVT&amp;cd=_C-NGkCQqQA&amp;usg=AFQjCNGYwVFitqxc83ez12rffrD_3OBhmg" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.newschannel5.com/story/18434286/clinical-trials-hope-to-help-fight-prevent-alzheimers&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://bostonglobe.com/news/nation/2012/05/15/clinical-trial-test-drugs-prevent-alzheimer-disease/8zgODTTkbdjOHLXyFzcSzK/story.html&amp;ct=ga&amp;cad=CAcQAhgAIAAoATABOAFA54vP_QRIAVAAWABiBWVuLVVT&amp;cd=_C-NGkCQqQA&amp;usg=AFQjCNEf2x9zfl0YBfcIYr7ULzUKORmKVw" style="color: #1111cc" target="_blank"><strong>Trial</strong> will test whether drug curbs form of Alzheimer&#8217;s</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">Boston Globe</a><br />
NEW YORK - In a <strong>clinical trial</strong>  that could lead to treatments that prevent Alzheimer&#8217;s disease, people  who are genetically guaranteed to suffer from the disease years from now  - but who do not yet have any symptoms - will for the first time be  given a <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://bostonglobe.com/news/nation/2012/05/15/clinical-trial-test-drugs-prevent-alzheimer-disease/8zgODTTkbdjOHLXyFzcSzK/story.html%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjABOAFA54vP_QRIAVAAWABiBWVuLVVT&amp;cd=_C-NGkCQqQA&amp;usg=AFQjCNGhYBKDuvIHvf_aYFOolgBHcjosxQ" style="color: #228822" title="http://news.google.com/news/story?ncl=http://bostonglobe.com/news/nation/2012/05/15/clinical-trial-test-drugs-prevent-alzheimer-disease/8zgODTTkbdjOHLXyFzcSzK/story.html&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/applied-clinical-intelligence-launches-icommittees-2012-05-16&amp;ct=ga&amp;cad=CAcQAhgAIAAoATACOAJA54vP_QRIAVAAWABiBWVuLVVT&amp;cd=_C-NGkCQqQA&amp;usg=AFQjCNHbHs1rYYavLC2RrjWlmXRgLWXrIw" style="color: #1111cc" target="_blank">Applied <strong>Clinical</strong> Intelligence Launches iCommittees</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
&#8220;Ultimately, our specialized technology and highly developed processes make better use of our clients&#8217; <strong>clinical trial</strong> resources.&#8221; The arrival of iCommittees corresponds with a growing demand for DMC and EAC involvement in <strong>clinical research</strong> trials.<br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/applied-clinical-intelligence-launches-icommittees-2012-05-16%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjACOAJA54vP_QRIAVAAWABiBWVuLVVT&amp;cd=_C-NGkCQqQA&amp;usg=AFQjCNGNSb_c29dr1YIPE38LxNnLtDtNxg" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/applied-clinical-intelligence-launches-icommittees-2012-05-16&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://health.heraldtribune.com/2012/05/15/drug-to-prevent-alzheimers-disease-gets-clinical-trial/&amp;ct=ga&amp;cad=CAcQAhgAIAAoATADOANA54vP_QRIAVAAWABiBWVuLVVT&amp;cd=_C-NGkCQqQA&amp;usg=AFQjCNFKozfK4c5my2iqP1HLw5MGnvyuyg" style="color: #1111cc" target="_blank">Drug to prevent Alzheimer&#8217;s disease gets <strong>clinical trial</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">Sarasota Herald-Tribune</a><br />
By The New York Times, Herald-Tribune In a <strong>clinical trial</strong>  that could lead to treatments that prevent Alzheimer&#8217;s disease, people  who are genetically guaranteed to suffer from the disease years from now  — but who do not yet have any symptoms — will <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://health.heraldtribune.com/2012/05/15/drug-to-prevent-alzheimers-disease-gets-clinical-trial/%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjADOANA54vP_QRIAVAAWABiBWVuLVVT&amp;cd=_C-NGkCQqQA&amp;usg=AFQjCNG0-ehen_L_vv2DgZ7NNaiw-v0RZA" style="color: #228822" title="http://news.google.com/news/story?ncl=http://health.heraldtribune.com/2012/05/15/drug-to-prevent-alzheimers-disease-gets-clinical-trial/&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.tampabay.com/news/localgovernment/clinical-drug-trial-facility-opens-in-new-port-richey-despite-zoning/1230294&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAEOARA54vP_QRIAVAAWABiBWVuLVVT&amp;cd=_C-NGkCQqQA&amp;usg=AFQjCNHHe3JlSh2MJ2wUPrl2QrU-Z-AT3w" style="color: #1111cc" target="_blank"><strong>Clinical</strong> drug <strong>trial</strong> facility opens in New Port Richey despite zoning objections</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">Tampabay.com</a><br />
By Robert Napper, Times Correspondent NEW PORT RICHEY — A company that conducts <strong>clinical</strong> drug <strong>trials</strong>  has opened its facility on Congress Street, in defiance of city  officials who told them months ago that a rezoning would be required.<br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.tampabay.com/news/localgovernment/clinical-drug-trial-facility-opens-in-new-port-richey-despite-zoning/1230294%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAEOARA54vP_QRIAVAAWABiBWVuLVVT&amp;cd=_C-NGkCQqQA&amp;usg=AFQjCNHas689xAx6UDk7UT-4DfBPyVbCvg" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.tampabay.com/news/localgovernment/clinical-drug-trial-facility-opens-in-new-port-richey-despite-zoning/1230294&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/nanostring-initiates-second-clinical-validation-study-for-breast-cancer-assay-2012-05-16&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAFOAVA54vP_QRIAVAAWABiBWVuLVVT&amp;cd=_C-NGkCQqQA&amp;usg=AFQjCNEWZWuVEzfDakZCbuueyt98RwRA2w" style="color: #1111cc" target="_blank">NanoString Initiates Second <strong>Clinical</strong> Validation Study for Breast Cancer Assay</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
SEATTLE,  May 16, 2012 (BUSINESS WIRE) &#8212; NanoString Technologies, Inc., a  privately held provider of life science tools for translational <strong>research</strong> and developer of molecular diagnostics, today announced the initiation of the second <strong>clinical</strong> validation <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/nanostring-initiates-second-clinical-validation-study-for-breast-cancer-assay-2012-05-16%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAFOAVA54vP_QRIAVAAWABiBWVuLVVT&amp;cd=_C-NGkCQqQA&amp;usg=AFQjCNGz6cWgAgtaILOTjaTM4wtHgRhwuw" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/nanostring-initiates-second-clinical-validation-study-for-breast-cancer-assay-2012-05-16&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px">
<table width="100%" border="0" cellpadding="0" cellspacing="0">
<tr>
<td valign="top"><a href="http://www.google.com/url?sa=X&amp;q=http://www.darkdaily.com/in-clinical-trials-breath-test-for-lung-cancer-shows-promise-for-earlier-detection-51612&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAGOAZA54vP_QRIAVAAWABiBWVuLVVT&amp;cd=_C-NGkCQqQA&amp;usg=AFQjCNHRYuXqRrG2d57c9j2l_AkG3Z1O5w" style="color: #1111cc" target="_blank">In <strong>Clinical Trials</strong>, Breath Test for Lung Cancer Shows Promise for Earlier <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">DARKDaily.com - Laboratory News</a><br />
First, researchers have completed the first <strong>clinical trial</strong> of a non-invasive cancer test that utilizes a breath specimen. Second, the subject of this <strong>clinical trial</strong> was lung cancer—a type of cancer that would benefit from a pathology test that can <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.darkdaily.com/in-clinical-trials-breath-test-for-lung-cancer-shows-promise-for-earlier-detection-51612%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAGOAZA54vP_QRIAVAAWABiBWVuLVVT&amp;cd=_C-NGkCQqQA&amp;usg=AFQjCNEJoANbLfisyL4dyTgayzpvTXJLfg" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.darkdaily.com/in-clinical-trials-breath-test-for-lung-cancer-shows-promise-for-earlier-detection-51612&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
<td align="center" valign="top" width="80"><a href="http://www.google.com/url?sa=X&amp;q=http://www.darkdaily.com/in-clinical-trials-breath-test-for-lung-cancer-shows-promise-for-earlier-detection-51612&amp;ct=ga&amp;cad=CAcQAhgAIAAoAjAGOAZA54vP_QRIAVAAWABiBWVuLVVT&amp;cd=_C-NGkCQqQA&amp;usg=AFQjCNHRYuXqRrG2d57c9j2l_AkG3Z1O5w" target="_blank"><img height="53" width="80" border="0" /></a><font size="-2"><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://www.darkdaily.com/in-clinical-trials-breath-test-for-lung-cancer-shows-promise-for-earlier-detection-51612&amp;ct=ga&amp;cad=CAcQAhgAIAAoAzAGOAZA54vP_QRIAVAAWABiBWVuLVVT&amp;cd=_C-NGkCQqQA&amp;usg=AFQjCNHRYuXqRrG2d57c9j2l_AkG3Z1O5w" target="_blank">DARKDaily.com - Laboratory News</a></font></td>
</tr>
</table>
</td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/onyx-pharmaceuticals-announces-data-presentations-at-48th-american-society-of-clinical-oncology-annual-meeting-2012-05-16&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAHOAdA54vP_QRIAVAAWABiBWVuLVVT&amp;cd=_C-NGkCQqQA&amp;usg=AFQjCNHgbrKZwxyU7vcZZS2E2Lb7gM-h6Q" style="color: #1111cc" target="_blank">Onyx Pharmaceuticals Announces Data Presentations at 48th American Society of <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
The  NDA submission is based on the Kyprolis 003-A1 study, an open-label,  single-arm Phase 2b trial, as well as safety data from additional  studies. A Phase 3 <strong>clinical trial</strong>, known as the ASPIRE trial, has completed enrollment and is evaluating the <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/onyx-pharmaceuticals-announces-data-presentations-at-48th-american-society-of-clinical-oncology-annual-meeting-2012-05-16%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAHOAdA54vP_QRIAVAAWABiBWVuLVVT&amp;cd=_C-NGkCQqQA&amp;usg=AFQjCNGbcQEig1dffJVHUPBbLPPbAUJTNQ" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/onyx-pharmaceuticals-announces-data-presentations-at-48th-american-society-of-clinical-oncology-annual-meeting-2012-05-16&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.sacbee.com/2012/05/15/4491499/one-year-evolve-trial-clinical.html&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAIOAhA54vP_QRIAVAAWABiBWVuLVVT&amp;cd=_C-NGkCQqQA&amp;usg=AFQjCNEMsEyVcqp-lJo70Pl58oSbwX14hA" style="color: #1111cc" target="_blank">One-Year EVOLVE <strong>Trial Clinical</strong> Results Confirm Comparable Safety And <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">Sacramento Bee</a><br />
The <strong>trial</strong> reported one-year <strong>clinical</strong>  and six-month intravascular ultrasound (IVUS) outcomes data, evaluating  the safety and effectiveness of the bioabsorbable abluminal  polymer-coated SYNERGY Stent. Results were presented today at the annual  EuroPCR <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.sacbee.com/2012/05/15/4491499/one-year-evolve-trial-clinical.html%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAIOAhA54vP_QRIAVAAWABiBWVuLVVT&amp;cd=_C-NGkCQqQA&amp;usg=AFQjCNFZhaQD9fl6mmdTfpi6eCnypcfxcA" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.sacbee.com/2012/05/15/4491499/one-year-evolve-trial-clinical.html&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.reuters.com/article/2012/05/16/roche-idUSWEA194420120516&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAJOAlA54vP_QRIAVAAWABiBWVuLVVT&amp;cd=_C-NGkCQqQA&amp;usg=AFQjCNFc5ktkD7CFLb9ZCJX8lNGXpfuY7g" style="color: #1111cc" target="_blank">Roche to present <strong>studies</strong> on advanced cancers at ASCO</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">Reuters</a><br />
ZURICH May 16 (Reuters) - Roche Holding AG will present late-stage <strong>clinical trial</strong>  data on drugs targeting advanced cancers at a key industry event next  month, as it seeks to prove it has enough armoury in its pipeline to  protect its oncology franchise.<br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.reuters.com/article/2012/05/16/roche-idUSWEA194420120516%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAJOAlA54vP_QRIAVAAWABiBWVuLVVT&amp;cd=_C-NGkCQqQA&amp;usg=AFQjCNFR4fRUYSPJsn7mbgCc5eU6swFPEw" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.reuters.com/article/2012/05/16/roche-idUSWEA194420120516&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
</table>
<table width="600px" border="0" cellpadding="0" cellspacing="0">
<tr>
<td style="background-color: #ebeff9; padding: 4px 8px">
<table width="100%" border="0" cellpadding="0" cellspacing="0">
<tr>
<td><font size="-1"><strong>Web</strong></font></td>
<td align="right" width="70%"><font size="-1"><strong>1</strong> new result for <strong>clinical trial</strong></font></td>
</tr>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://sanfrancisco.cbslocal.com/2012/05/15/south-san-francisco-based-genentech-starts-clinical-trial-on-alzheimers/&amp;ct=ga&amp;cad=CAcQAhgAIAEoATAKOABA54vP_QRIAVgAYgVlbi1VUw&amp;cd=_C-NGkCQqQA&amp;usg=AFQjCNFnmYXvyhpCaCi1EyAcDyHzgLw55g" style="color: #1111cc" target="_blank">South San Francisco-Based Genentech Starts <strong>Clinical Trial</strong> On <strong>&#8230;</strong></a><br />
<font size="-1">Genentech  is studying whether intervention can stop Alzheimer&#8217;s from developing  in people genetically predisposed to the disease.<br />
<a href="http://www.google.com/url?sa=X&amp;q=http://sanfrancisco.cbslocal.com/2012/05/15/south-san-francisco-based-genentech-starts-clinical-trial-on-alzheimers/&amp;ct=ga&amp;cad=CAcQAhgAIAEoBDAKOABA54vP_QRIAVgAYgVlbi1VUw&amp;cd=_C-NGkCQqQA&amp;usg=AFQjCNFnmYXvyhpCaCi1EyAcDyHzgLw55g" style="color: #228822" title="http://sanfrancisco.cbslocal.com/2012/05/15/south-san-francisco-based-genentech-starts-clinical-trial-on-alzheimers/" target="_blank">sanfrancisco.cbslocal.com/&#8230;/<wbr></wbr>south-san-francisco-based-<wbr></wbr>genent&#8230;</a></font></td>
</tr>
</table>
]]></content:encoded>
			<wfw:commentRss>http://societyofcollegemedicine.com/2012/05/16/clinical-news-we-are-currently-tracking-4/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Clinical news we are currently tracking&#8230;</title>
		<link>http://societyofcollegemedicine.com/2012/05/10/clinical-news-we-are-currently-tracking-3/</link>
		<comments>http://societyofcollegemedicine.com/2012/05/10/clinical-news-we-are-currently-tracking-3/#comments</comments>
		<pubDate>Thu, 10 May 2012 16:20:34 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://societyofcollegemedicine.com/2012/05/10/clinical-news-we-are-currently-tracking-3/</guid>
		<description><![CDATA[




News
9 new results for clinical trial








OnCore Version 12.0 Delivers Robust Functionality for Supporting Clinical &#8230;
MarketWatch (press release)
The new version of the OnCore clinical research  management system offers a comprehensive Coverage Analysis module to  assist institutions with maintaining billing compliance. MADISON, Wis.,  May 10, 2012 /PRNewswire via COMTEX/ &#8212; Forte Research Systems, &#8230;
See [...]]]></description>
			<content:encoded><![CDATA[<table width="600px" border="0" cellpadding="0" cellspacing="0">
<tr>
<td style="background-color: #ebeff9; padding: 4px 8px">
<table width="100%" border="0" cellpadding="0" cellspacing="0">
<tr>
<td><font size="-1"><strong>News</strong></font></td>
<td align="right" width="70%"><font size="-1"><strong>9</strong> new results for <strong>clinical trial</strong></font></td>
</tr>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/oncore-version-120-delivers-robust-functionality-for-supporting-clinical-research-billing-compliance-2012-05-10&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAAOABAt7qv_QRIAVAAWABiBWVuLVVT&amp;cd=rrE3NBpiVAE&amp;usg=AFQjCNE2RAGRj_ZQBuS2qgaLFfIDmEViqA" style="color: #1111cc" target="_blank">OnCore Version 12.0 Delivers Robust Functionality for Supporting <strong>Clinical</strong> <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
The new version of the OnCore <strong>clinical research</strong>  management system offers a comprehensive Coverage Analysis module to  assist institutions with maintaining billing compliance. MADISON, Wis.,  May 10, 2012 /PRNewswire via COMTEX/ &#8212; Forte Research Systems, <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/oncore-version-120-delivers-robust-functionality-for-supporting-clinical-research-billing-compliance-2012-05-10%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAAOABAt7qv_QRIAVAAWABiBWVuLVVT&amp;cd=rrE3NBpiVAE&amp;usg=AFQjCNFZFNRBM1rFAzcpseapxEXI5wLYJA" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/oncore-version-120-delivers-robust-functionality-for-supporting-clinical-research-billing-compliance-2012-05-10&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.businessweek.com/news/2012-05-09/indian-drug-regulator-accused-of-corruption-and-collusion&amp;ct=ga&amp;cad=CAcQAhgAIAAoATABOAFAt7qv_QRIAVAAWABiBWVuLVVT&amp;cd=rrE3NBpiVAE&amp;usg=AFQjCNGlxTwGrjtdpwinV_B7A4yZl8NVfQ" style="color: #1111cc" target="_blank">Indian Drug Regulator Accused of Corruption and Collusion</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">BusinessWeek (blog)</a><br />
By  Adi Narayan and Siddharth Philip on May 10, 2012 India&#8217;s top drug  regulatory agency violated laws and colluded with pharmaceutical  companies to approve medicines without <strong>clinical trials</strong>, a parliamentary panel said in a report.<br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.businessweek.com/news/2012-05-09/indian-drug-regulator-accused-of-corruption-and-collusion%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjABOAFAt7qv_QRIAVAAWABiBWVuLVVT&amp;cd=rrE3NBpiVAE&amp;usg=AFQjCNF4DpoH-52NJ_sVHi4m-yj9WJDmBA" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.businessweek.com/news/2012-05-09/indian-drug-regulator-accused-of-corruption-and-collusion&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.sacbee.com/2012/05/09/4478507/clinical-trial-update-stem-cell.html&amp;ct=ga&amp;cad=CAcQAhgAIAAoATACOAJAt7qv_QRIAVAAWABiBWVuLVVT&amp;cd=rrE3NBpiVAE&amp;usg=AFQjCNEhpb9Vw6WQw5vkhLqiLy3sVGJ6ow" style="color: #1111cc" target="_blank"><strong>Clinical trial</strong> update: Stem cell study for ALS (Lou Gehrig&#8217;s disease)</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">Sacramento Bee</a><br />
&#8220;We believe that the cells and the route of administration are safe,&#8221; says Feldman, who is the principal investigator of the <strong>trial</strong> and the director of the UM&#8217;s A. Alfred Taubman Medical <strong>Research</strong> Institute. &#8220;The FDA go-ahead to bring these three <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.sacbee.com/2012/05/09/4478507/clinical-trial-update-stem-cell.html%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjACOAJAt7qv_QRIAVAAWABiBWVuLVVT&amp;cd=rrE3NBpiVAE&amp;usg=AFQjCNHqtw6M4fsn4N-8rOsfxXmLNYnHbw" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.sacbee.com/2012/05/09/4478507/clinical-trial-update-stem-cell.html&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/pharpoint-research-is-recipient-of-ceds-north-carolina-companies-to-watch-award-2012-05-10&amp;ct=ga&amp;cad=CAcQAhgAIAAoATADOANAt7qv_QRIAVAAWABiBWVuLVVT&amp;cd=rrE3NBpiVAE&amp;usg=AFQjCNEGpB3vJf5DHXRWReots70sH2smkw" style="color: #1111cc" target="_blank">PharPoint <strong>Research</strong> is Recipient of CED&#8217;s North Carolina Companies to Watch Award</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
<strong>RESEARCH</strong> TRIANGLE PARK &amp; WILMINGTON, NC, May 10, 2012 (BUSINESS WIRE) &#8212; PharPoint <strong>Research</strong>, Inc., an innovative drug development service provider offering expertise in project management, <strong>clinical</strong> monitoring, data management and biostatistics services <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/pharpoint-research-is-recipient-of-ceds-north-carolina-companies-to-watch-award-2012-05-10%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjADOANAt7qv_QRIAVAAWABiBWVuLVVT&amp;cd=rrE3NBpiVAE&amp;usg=AFQjCNHy9fEvL3KvuO03PBHtl-8sq3gQHg" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/pharpoint-research-is-recipient-of-ceds-north-carolina-companies-to-watch-award-2012-05-10&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.fiercebiotech.com/story/subpar-clinical-trials-probed-indias-review-regulation/2012-05-10&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAEOARAt7qv_QRIAVAAWABiBWVuLVVT&amp;cd=rrE3NBpiVAE&amp;usg=AFQjCNEdKpErNdbNIPi-ZciDHh9DMQv4Dg" style="color: #1111cc" target="_blank">Subpar <strong>clinical trials</strong> probed in India&#8217;s review of regulation</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">FierceBiotech</a><br />
Indian  lawmakers and patient advocates charge that their regulator  rubber-stamped drugs to be sold in the county without required <strong>clinical trials</strong>. And a parliamentary report heaps blame for poor adherence to trials standards on Big Pharma groups, <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.fiercebiotech.com/story/subpar-clinical-trials-probed-indias-review-regulation/2012-05-10%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAEOARAt7qv_QRIAVAAWABiBWVuLVVT&amp;cd=rrE3NBpiVAE&amp;usg=AFQjCNF4vEnEM2lkY5qnH6bSM_UfZ8x6Gw" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.fiercebiotech.com/story/subpar-clinical-trials-probed-indias-review-regulation/2012-05-10&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/medicure-announces-commencement-of-enrollment-in-savi-pci-trial-of-aggrastat-2012-05-10-731280%3Freflink%3DMW_news_stmp&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAFOAVAt7qv_QRIAVAAWABiBWVuLVVT&amp;cd=rrE3NBpiVAE&amp;usg=AFQjCNHbX3auh06igsAWjvyLf8d6YCsi0g" style="color: #1111cc" target="_blank">Medicure Announces Commencement of Enrollment in SAVI-PCI <strong>Trial</strong> of AGGRASTAT</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
Both facilities are part of the cardiovascular <strong>clinical</strong> site network of the Sarah Cannon <strong>Research</strong>  Institute (SCRI), Nashville, TN. &#8220;We are pleased to see the  commencement of enrollment at two of our leading facilities and we look  forward to seeing all <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/medicure-announces-commencement-of-enrollment-in-savi-pci-trial-of-aggrastat-2012-05-10-731280%253Freflink%253DMW_news_stmp%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAFOAVAt7qv_QRIAVAAWABiBWVuLVVT&amp;cd=rrE3NBpiVAE&amp;usg=AFQjCNG57WIDO4f0s-JAGOgX-3Ch8t3Njg" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/medicure-announces-commencement-of-enrollment-in-savi-pci-trial-of-aggrastat-2012-05-10-731280%3Freflink%3DMW_news_stmp&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://online.wsj.com/article/SB10001424052702304070304577395960042733168.html&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAGOAZAt7qv_QRIAVAAWABiBWVuLVVT&amp;cd=rrE3NBpiVAE&amp;usg=AFQjCNEAWbABFB2sOwJM4iKfWNHMpUqdBA" style="color: #1111cc" target="_blank">Drug Makers Refute India Probe Findings</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">Wall Street Journal</a><br />
GlaxoSmithKline PLC said in a statement the company was granted a waiver on conducting <strong>clinical trials</strong>  in India for ambrisentan, its drug to treat pulmonary arterial  hypertension, as local rules allow such a concession for drugs to treat a  &#8220;rare <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://online.wsj.com/article/SB10001424052702304070304577395960042733168.html%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAGOAZAt7qv_QRIAVAAWABiBWVuLVVT&amp;cd=rrE3NBpiVAE&amp;usg=AFQjCNGggMcyzxvkQOMXsjUAB6OrNhlbDg" style="color: #228822" title="http://news.google.com/news/story?ncl=http://online.wsj.com/article/SB10001424052702304070304577395960042733168.html&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/cytrx-reports-first-quarter-2012-financial-results-2012-05-10&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAHOAdAt7qv_QRIAVAAWABiBWVuLVVT&amp;cd=rrE3NBpiVAE&amp;usg=AFQjCNHq7rLKSMy1bHdU-bfEBrxSy6kjBw" style="color: #1111cc" target="_blank">CytRx Reports First Quarter 2012 Financial Results</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
&#8220;Last month, we initiated a Phase 2 <strong>clinical trial</strong>  in patients with advanced pancreatic ductual adenocarcinomas who have  either relapsed or did not respond to other chemotherapies. We are  gratified that the renowned pancreatic cancer expert Dr. Daniel <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/cytrx-reports-first-quarter-2012-financial-results-2012-05-10%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAHOAdAt7qv_QRIAVAAWABiBWVuLVVT&amp;cd=rrE3NBpiVAE&amp;usg=AFQjCNHvm8pkOGw8qffIEa5kqsBdLTeMeg" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/cytrx-reports-first-quarter-2012-financial-results-2012-05-10&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/seattle-genetics-announces-data-from-investigator-trial-of-adcetristm-in-relapsed-cutaneous-t-cell-lymphoma-2012-05-10&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAIOAhAt7qv_QRIAVAAWABiBWVuLVVT&amp;cd=rrE3NBpiVAE&amp;usg=AFQjCNEMpzHNo1HF1q5eMH2V0bsLuH49_A" style="color: #1111cc" target="_blank">Seattle Genetics Announces Data from Investigator <strong>Trial</strong> of ADCETRIS(TM) in <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
BOTHELL,  Wash., May 10, 2012 (BUSINESS WIRE) &#8212; Seattle Genetics, Inc.  (NASDAQ:SGEN) today announced that interim results from an  investigator-sponsored phase II <strong>clinical trial</strong> of ADCETRIS (brentuximab vedotin) in patients with relapsed cutaneous <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/seattle-genetics-announces-data-from-investigator-trial-of-adcetristm-in-relapsed-cutaneous-t-cell-lymphoma-2012-05-10%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAIOAhAt7qv_QRIAVAAWABiBWVuLVVT&amp;cd=rrE3NBpiVAE&amp;usg=AFQjCNH-JUDAv4HadqDDffPCjojcQU9Jmw" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/seattle-genetics-announces-data-from-investigator-trial-of-adcetristm-in-relapsed-cutaneous-t-cell-lymphoma-2012-05-10&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
</table>
<table width="600px" border="0" cellpadding="0" cellspacing="0">
<tr>
<td style="background-color: #ebeff9; padding: 4px 8px">
<table width="100%" border="0" cellpadding="0" cellspacing="0">
<tr>
<td><font size="-1"><strong>Blogs</strong></font></td>
<td align="right" width="70%"><font size="-1"><strong>5</strong> new results for <strong>clinical trial</strong></font></td>
</tr>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://detroit.cbslocal.com/2012/05/09/dmc-cardiovascular-institute-in-new-pad-clinical-trial/&amp;ct=ga&amp;cad=CAcQAhgAIAIoATAJOABAt7qv_QRIAVgAYgVlbi1VUw&amp;cd=rrE3NBpiVAE&amp;usg=AFQjCNFDCS-UdfhD5lATT3wpElBQvGVr5w" style="color: #1111cc" target="_blank">DMC Cardiovascular Institute In New PAD <strong>Clinical Trial</strong> « CBS Detroit</a><br />
<font size="-1"><font color="#777777">By Matt Roush</font><br />
The DMC Cardiovascular Institute announced Wednesday that it will participate in Connect II, a global <em>clinical trial</em> conditionally approved by the FDA that gives physicians access to Ocelot, a new imaging technology tool to fight Peripheral <strong>&#8230;</strong><br />
<font color="#228822">CBS Detroit</font></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.imedicalapps.com/2012/05/gingerio-recruiting-ibd-ulcerative-colitis-patients-clinical-trial/&amp;ct=ga&amp;cad=CAcQAhgAIAIoATAKOAFAt7qv_QRIAVgAYgVlbi1VUw&amp;cd=rrE3NBpiVAE&amp;usg=AFQjCNHxZZNM2G7Mh41z9MshHdH3A3zR-Q" style="color: #1111cc" target="_blank">Ginger.io is recruiting IBD and ulcerative colitis patients for <strong>clinical trial</strong></a><br />
<font size="-1"><font color="#777777">By Brian Edwards</font><br />
Ginger.io is seeking adolescent Crohn&#8217;s Disease and ulcerative colitis patients for a <em>clinical trial</em> of its passive sensing application.<br />
<font color="#228822">iMedicalApps</font></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.benzinga.com/news/12/05/2574380/alnylam-presents-final-results-from-a-phase-i-clinical-trial-of-aln-ttr01-an-rnai&amp;ct=ga&amp;cad=CAcQAhgAIAIoATALOAJAt7qv_QRIAVgAYgVlbi1VUw&amp;cd=rrE3NBpiVAE&amp;usg=AFQjCNHpjt4ihOBT7UUl4VSRVECsAJqxEw" style="color: #1111cc" target="_blank">Alnylam Presents Final Results from a Phase I <strong>Clinical Trial</strong> of ALN <strong>&#8230;</strong></a><br />
<font size="-1"><font color="#777777">By Eddie Staley</font><br />
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today final results from its completed Phase I <em>clinical trial</em> with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).<br />
<font color="#228822">Benzinga - Stock Market Quotes,&#8230;</font></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.pharmiweb.com/careers/results.asp%3FROW_ID%3D603936&amp;ct=ga&amp;cad=CAcQAhgAIAIoATAMOANAt7qv_QRIAVgAYgVlbi1VUw&amp;cd=rrE3NBpiVAE&amp;usg=AFQjCNFU_ZD5dtmPEhR8ssoa7GWYF7ZXaA" style="color: #1111cc" target="_blank">Job Detail | <strong>Clinical Trial</strong> Specialist | PharmiWeb.com</a><br />
<font size="-1">Pharmaceutical job vacancy : <em>Clinical Trial</em> Specialist |<br />
<font color="#228822">Latest Clinical Research Jobs</font></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.drugs.com/clinical_trials/bellus-health-announces-update-phase-iii-trial-kiacta-aa-amyloidosis-presented-xiii-international-13506.html&amp;ct=ga&amp;cad=CAcQAhgAIAIoATANOARAt7qv_QRIAVgAYgVlbi1VUw&amp;cd=rrE3NBpiVAE&amp;usg=AFQjCNEqBUDYcX2b8TJJIolyYDuymFENVw" style="color: #1111cc" target="_blank">BELLUS Health announces update on the Phase III <strong>trial</strong> for KIACTA <strong>&#8230;</strong></a><br />
<font size="-1">The  Phase III study is an event-driven trial that is being conducted in  approximately 28 countries, across 79 sites. The current trial is being  run to confirm the results of the prior Phase III <em>clinical trial</em>, which demonstrated statistically significant <strong>&#8230;</strong><br />
<font color="#228822">Drugs.com - Clinical Trials</font></font></td>
</tr>
</table>
]]></content:encoded>
			<wfw:commentRss>http://societyofcollegemedicine.com/2012/05/10/clinical-news-we-are-currently-tracking-3/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Clinical news we are currently tracking&#8230;</title>
		<link>http://societyofcollegemedicine.com/2012/05/02/clinical-news-we-are-currently-tracking-2/</link>
		<comments>http://societyofcollegemedicine.com/2012/05/02/clinical-news-we-are-currently-tracking-2/#comments</comments>
		<pubDate>Wed, 02 May 2012 16:30:30 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://societyofcollegemedicine.com/2012/05/02/clinical-news-we-are-currently-tracking-2/</guid>
		<description><![CDATA[




News
10 new results for clinical trial











Clinical trials often fall short
Mother Nature Network
Most clinical trials  for cancer, heart disease and mental health are too small to offer  adequate medical evidence, said a review. By Agence France-PresseTue,  May 01 2012 at 4:08 PM EST TRIALS: Ninety-six percent of those trials  had fewer than [...]]]></description>
			<content:encoded><![CDATA[<table border="0" cellpadding="0" cellspacing="0" width="600px">
<tr>
<td style="background-color: #ebeff9; padding: 4px 8px">
<table border="0" cellpadding="0" cellspacing="0" width="100%">
<tr>
<td><font size="-1"><strong>News</strong></font></td>
<td align="right" width="70%"><font size="-1"><strong>10</strong> new results for <strong>clinical trial</strong></font></td>
</tr>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px">
<table border="0" cellpadding="0" cellspacing="0" width="100%">
<tr>
<td valign="top"><a href="http://www.google.com/url?sa=X&amp;q=http://www.mnn.com/health/fitness-well-being/stories/clinical-trials-often-fall-short&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAAOABAw6CF_QRIAVAAWABiBWVuLVVT&amp;cd=aTdRJppknhc&amp;usg=AFQjCNEJLlxnFD-cWrRagim6SlTuuJZ5Ug" style="color: #1111cc" target="_blank"><strong>Clinical trials</strong> often fall short</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">Mother Nature Network</a><br />
Most <strong>clinical trials</strong>  for cancer, heart disease and mental health are too small to offer  adequate medical evidence, said a review. By Agence France-PresseTue,  May 01 2012 at 4:08 PM EST TRIALS: Ninety-six percent of those trials  had fewer than 1000 <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.mnn.com/health/fitness-well-being/stories/clinical-trials-often-fall-short%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAAOABAw6CF_QRIAVAAWABiBWVuLVVT&amp;cd=aTdRJppknhc&amp;usg=AFQjCNFoFYI0mL3bJc7n-uraryy4bdl-iA" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.mnn.com/health/fitness-well-being/stories/clinical-trials-often-fall-short&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
<td align="center" valign="top" width="80"><a href="http://www.google.com/url?sa=X&amp;q=http://www.mnn.com/health/fitness-well-being/stories/clinical-trials-often-fall-short&amp;ct=ga&amp;cad=CAcQAhgAIAAoAjAAOABAw6CF_QRIAVAAWABiBWVuLVVT&amp;cd=aTdRJppknhc&amp;usg=AFQjCNEJLlxnFD-cWrRagim6SlTuuJZ5Ug" target="_blank"><img height="45" border="0" width="80" /></a><font size="-2"><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://www.mnn.com/health/fitness-well-being/stories/clinical-trials-often-fall-short&amp;ct=ga&amp;cad=CAcQAhgAIAAoAzAAOABAw6CF_QRIAVAAWABiBWVuLVVT&amp;cd=aTdRJppknhc&amp;usg=AFQjCNEJLlxnFD-cWrRagim6SlTuuJZ5Ug" target="_blank">Mother Nature Network</a></font></td>
</tr>
</table>
</td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/clinical-trial-shows-sentra-pmr-improves-quality-of-sleep-2012-05-02&amp;ct=ga&amp;cad=CAcQAhgAIAAoATABOAFAw6CF_QRIAVAAWABiBWVuLVVT&amp;cd=aTdRJppknhc&amp;usg=AFQjCNE2DH2XaUeMn_rbkaCpoHa8rrPUrQ" style="color: #1111cc" target="_blank"><strong>Clinical Trial</strong> Shows Sentra PM(R) Improves Quality of Sleep</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
<strong>&#8230;</strong>  Inc., a specialty pharmaceutical company that manufactures and  distributes specialty pharmaceuticals to physicians, pharmacies and  skilled nursing facilities, published results from a <strong>clinical trial</strong> of the proprietary medical food Sentra PM.<br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/clinical-trial-shows-sentra-pmr-improves-quality-of-sleep-2012-05-02%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjABOAFAw6CF_QRIAVAAWABiBWVuLVVT&amp;cd=aTdRJppknhc&amp;usg=AFQjCNF6FLO6keXiBfN2sZWeHd5BFdNEHg" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/clinical-trial-shows-sentra-pmr-improves-quality-of-sleep-2012-05-02&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.medscape.com/viewarticle/763026&amp;ct=ga&amp;cad=CAcQAhgAIAAoATACOAJAw6CF_QRIAVAAWABiBWVuLVVT&amp;cd=aTdRJppknhc&amp;usg=AFQjCNEHcuVfrX6fzJCOc2aButidOqcoFA" style="color: #1111cc" target="_blank">Many <strong>Clinical Trials</strong> Unable to Supply High-Quality Evidence</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">Medscape</a><br />
May 1, 2012 — Many interventional <strong>clinical trials</strong>  are small, with significant heterogeneity in the methods used,  including blinding, randomization, and the use of data monitoring  committees (DMCs), according to a study of <strong>clinical trials</strong> registered at <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.medscape.com/viewarticle/763026%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjACOAJAw6CF_QRIAVAAWABiBWVuLVVT&amp;cd=aTdRJppknhc&amp;usg=AFQjCNFqmcHGVcdXnmU-DZfL5-B8zERChw" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.medscape.com/viewarticle/763026&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/novavax-launches-phase-i-clinical-trial-of-ah5n1-influenza-vaccine-candidate-2012-05-02&amp;ct=ga&amp;cad=CAcQAhgAIAAoATADOANAw6CF_QRIAVAAWABiBWVuLVVT&amp;cd=aTdRJppknhc&amp;usg=AFQjCNEPh5JTYFhaHlz-4cWgI42UsNX7Tw" style="color: #1111cc" target="_blank">NOVAVAX Launches Phase I <strong>Clinical Trial</strong> of A/H5N1 Influenza Vaccine Candidate</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
ROCKVILLE,  Md., May 2, 2012 (GlobeNewswire via COMTEX) &#8212; Novavax, Inc.  (NASDAQ:NVAX) announced today that it has begun enrollment in a Phase I <strong>clinical trial</strong> of its monovalent virus-like particle (VLP) vaccine candidate to prevent a potential pandemic <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/novavax-launches-phase-i-clinical-trial-of-ah5n1-influenza-vaccine-candidate-2012-05-02%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjADOANAw6CF_QRIAVAAWABiBWVuLVVT&amp;cd=aTdRJppknhc&amp;usg=AFQjCNHMMcpqftwGBB5bnTBrsXTWgRTUNg" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/novavax-launches-phase-i-clinical-trial-of-ah5n1-influenza-vaccine-candidate-2012-05-02&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/echo-therapeutics-announces-positive-clinical-trial-results-of-symphony-tcgm-system-2012-05-02&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAEOARAw6CF_QRIAVAAWABiBWVuLVVT&amp;cd=aTdRJppknhc&amp;usg=AFQjCNExtkYkn7DONVA1XbwpSzVM45g3jQ" style="color: #1111cc" target="_blank">Echo Therapeutics Announces Positive <strong>Clinical Trial</strong> Results of Symphony® tCGM <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
<strong>&#8230;</strong>  wireless, transdermal continuous glucose monitoring system and its  Prelude® SkinPrep System for transdermal drug delivery, today announced  positive results from its <strong>clinical trial</strong> of the Symphony tCGM System in elective cardiac surgery patients.<br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/echo-therapeutics-announces-positive-clinical-trial-results-of-symphony-tcgm-system-2012-05-02%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAEOARAw6CF_QRIAVAAWABiBWVuLVVT&amp;cd=aTdRJppknhc&amp;usg=AFQjCNEgl9yz9ZQmSxQsrA8q7044Yav9bQ" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/echo-therapeutics-announces-positive-clinical-trial-results-of-symphony-tcgm-system-2012-05-02&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.timesunion.com/business/press-releases/article/Verified-Clinical-Trials-Presents-at-the-3526647.php&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAFOAVAw6CF_QRIAVAAWABiBWVuLVVT&amp;cd=aTdRJppknhc&amp;usg=AFQjCNFmoSkDI2tvcXZA_g-7KYK6ms0J7Q" style="color: #1111cc" target="_blank">Verified <strong>Clinical Trials</strong> Presents at the Partnerships in <strong>Clinical Trials</strong> 2012 <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">Albany Times Union</a><br />
Verified <strong>Clinical Trials</strong> (VCT) a recognized expert in the field of dual enrollment in <strong>clinical trials</strong> presents at the Partnerships In <strong>Clinical Trials</strong> 2012 meeting to review the issues and definitive solutions regarding this serious problem.<br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.timesunion.com/business/press-releases/article/Verified-Clinical-Trials-Presents-at-the-3526647.php%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAFOAVAw6CF_QRIAVAAWABiBWVuLVVT&amp;cd=aTdRJppknhc&amp;usg=AFQjCNHL6BfXlVpVjOFS3r8EU5L9J-wlqA" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.timesunion.com/business/press-releases/article/Verified-Clinical-Trials-Presents-at-the-3526647.php&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://health.usnews.com/health-news/news/articles/2012/05/01/analysis-finds-clinical-trials-often-small-of-poor-quality&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAGOAZAw6CF_QRIAVAAWABiBWVuLVVT&amp;cd=aTdRJppknhc&amp;usg=AFQjCNHKyPbpvGQjB-5sUXTZRHmPCefDHg" style="color: #1111cc" target="_blank">Analysis Finds <strong>Clinical Trials</strong> Often Small, of Poor Quality</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">U.S. News &amp; World Report</a><br />
By Randy Dotinga TUESDAY, May 1 (HealthDay News) &#8212; A new analysis of registered US <strong>clinical trials</strong>  &#8212; the research that seeks to determine if medical treatments and  prevention strategies work &#8212; finds that many are small and of poor  quality.<br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://health.usnews.com/health-news/news/articles/2012/05/01/analysis-finds-clinical-trials-often-small-of-poor-quality%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAGOAZAw6CF_QRIAVAAWABiBWVuLVVT&amp;cd=aTdRJppknhc&amp;usg=AFQjCNF2JprwBK4DjEMKUdMb5gTKINytbg" style="color: #228822" title="http://news.google.com/news/story?ncl=http://health.usnews.com/health-news/news/articles/2012/05/01/analysis-finds-clinical-trials-often-small-of-poor-quality&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.healthimaging.com/index.php%3Foption%3Dcom_articles%26view%3Darticle%26id%3D33804:jama-feature-most-clinical-trials-fail-to-add-meaningful-evidence-&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAHOAdAw6CF_QRIAVAAWABiBWVuLVVT&amp;cd=aTdRJppknhc&amp;usg=AFQjCNFXChi1Z36O7j7qPjiNM-a-bB2YcA" style="color: #1111cc" target="_blank">JAMA feature: Most <strong>clinical trials</strong> fail to add meaningful evidence</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">Health Imaging</a><br />
If randomized controlled <strong>clinical trials</strong>  are the gold standard for advancing knowledge in medical care, then the  research community has been panning more particles than nuggets. That  is the finding of a comprehensive analysis that focused on <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.healthimaging.com/index.php%253Foption%253Dcom_articles%2526view%253Darticle%2526id%253D33804:jama-feature-most-clinical-trials-fail-to-add-meaningful-evidence-%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAHOAdAw6CF_QRIAVAAWABiBWVuLVVT&amp;cd=aTdRJppknhc&amp;usg=AFQjCNHWLDyOi-CPz_K8DzjMDE49SHqOAw" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.healthimaging.com/index.php%3Foption%3Dcom_articles%26view%3Darticle%26id%3D33804:jama-feature-most-clinical-trials-fail-to-add-meaningful-evidence-&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/isr-profiles-the-state-of-patient-recruitment-in-clinical-trials-2012-05-02&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAIOAhAw6CF_QRIAVAAWABiBWVuLVVT&amp;cd=aTdRJppknhc&amp;usg=AFQjCNGOF03MaXeLXQAkjET_Q-L8Ja1xqA" style="color: #1111cc" target="_blank">ISR Profiles the State of Patient Recruitment in <strong>Clinical Trials</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
CARY,  NC, May 02, 2012 (BUSINESS WIRE) &#8212; Industry Standard Research (ISR)  today announced the availability of a new report titled The State of  Patient Recruitment in <strong>Clinical Trials</strong> that provides sponsors and service providers with valuable insight <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/isr-profiles-the-state-of-patient-recruitment-in-clinical-trials-2012-05-02%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAIOAhAw6CF_QRIAVAAWABiBWVuLVVT&amp;cd=aTdRJppknhc&amp;usg=AFQjCNH6AWnDW2VFDTtipwrcRowB8lrXnA" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/isr-profiles-the-state-of-patient-recruitment-in-clinical-trials-2012-05-02&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.sunherald.com/2012/05/01/3919200/gilead-initiates-phase-3-clinical.html&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAJOAlAw6CF_QRIAVAAWABiBWVuLVVT&amp;cd=aTdRJppknhc&amp;usg=AFQjCNGhnmPPbra6eC9Gmh_pqh7PKv1svQ" style="color: #1111cc" target="_blank">Gilead Initiates Phase 3 <strong>Clinical Trial</strong> Evaluating GS-1101 for the Treatment <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">SunHerald.com</a><br />
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the first patient has been dosed in a Phase 3 <strong>clinical trial</strong>  evaluating the efficacy and safety of GS-1101 (formerly CAL-101).  GS-1101 is an investigational, first-in-class specific inhibitor of <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.sunherald.com/2012/05/01/3919200/gilead-initiates-phase-3-clinical.html%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAJOAlAw6CF_QRIAVAAWABiBWVuLVVT&amp;cd=aTdRJppknhc&amp;usg=AFQjCNF3jr1at4DvN5q-E3wZUSzrgfvaXQ" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.sunherald.com/2012/05/01/3919200/gilead-initiates-phase-3-clinical.html&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" width="600px">
<tr>
<td style="background-color: #ebeff9; padding: 4px 8px">
<table border="0" cellpadding="0" cellspacing="0" width="100%">
<tr>
<td><font size="-1"><strong>Blogs</strong></font></td>
<td align="right" width="70%"><font size="-1"><strong>5</strong> new results for <strong>clinical trial</strong></font></td>
</tr>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.healthfinder.gov/news/newsstory.aspx%3FDocid%3D664335&amp;ct=ga&amp;cad=CAcQAhgAIAIoATAKOABAw6CF_QRIAVgAYgVlbi1VUw&amp;cd=aTdRJppknhc&amp;usg=AFQjCNEo1AFpeES1eMPW3ojPP2mDtNN16Q" style="color: #1111cc" target="_blank">Analysis Finds <strong>Clinical Trials</strong> Often Small, of Poor Quality <strong>&#8230;</strong></a><br />
<font size="-1">TUESDAY, May 1 (HealthDay News) &#8212; A new analysis of registered U.S. <em>clinical trials</em>  &#8212; the research that seeks to determine if medical treatments and  prevention strategies work &#8212; finds that many are small and of poor  quality. Studies of <strong>&#8230;</strong><br />
<font color="#228822"><a href="http://healthfinder.gov/" target="_blank">healthfinder.gov</a> Daily News</font></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.fyibehealthy.com/2012/05/02/clinical-trials-answer-all-study/&amp;ct=ga&amp;cad=CAcQAhgAIAIoATALOAFAw6CF_QRIAVgAYgVlbi1VUw&amp;cd=aTdRJppknhc&amp;usg=AFQjCNErPSvbvy-op_eaqhW8ST9ssV3XQQ" style="color: #1111cc" target="_blank"><strong>Clinical trials</strong> don&#8217;t answer all, study says | FYI BeHealthy</a><br />
<font size="-1"><font color="#777777">By Editor</font><br />
(AFP)Most <em>clinical trials</em>  for cancer, heart disease and mental health are too small to offer  adequate medical evidence, said a review of the US database of such  studies released on Tuesday. The analysis in the Journal of the American  Medical <strong>&#8230;</strong><br />
<font color="#228822">FYI BeHealthy</font></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.drugs.com/news/clinstar-present-outsourcing-clinical-trials-europe-37935.html&amp;ct=ga&amp;cad=CAcQAhgAIAIoATAMOAJAw6CF_QRIAVgAYgVlbi1VUw&amp;cd=aTdRJppknhc&amp;usg=AFQjCNF51B4IoMLXACZYXwuZYf1uk7_O8g" style="color: #1111cc" target="_blank">ClinStar to Present at Outsourcing in <strong>Clinical Trials</strong> Europe - Drugs <strong>&#8230;</strong></a><br />
<font size="-1">David Passov to Speak on Successfully Conducting <em>Clinical Trials</em> in Russia and parts of Eastern Europe May 1, 2012 - ClinStar, LLC, an established clinical rese.<br />
<font color="#228822">Drugs.com - Pharma News</font></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.drugs.com/clinical_trials/zalicus-advancing-z160-novel-oral-n-type-calcium-channel-blocker-into-multiple-phase-2a-clinical-13432.html&amp;ct=ga&amp;cad=CAcQAhgAIAIoATANOANAw6CF_QRIAVgAYgVlbi1VUw&amp;cd=aTdRJppknhc&amp;usg=AFQjCNG_cjtZMIBo116a80t9u2vXKq59FA" style="color: #1111cc" target="_blank">Zalicus Advancing Z160, Its Novel, Oral N-type Calcium Channel <strong>&#8230;</strong></a><br />
<font size="-1">Optimal Formulation Selected For Clinical Use First Phase 2a <em>Clinical Trial</em> to Initiate Third Quarter 2012 May 2, 2012 - Zalicus Inc. (NASDAQ ZLCS), a biopharma.<br />
<font color="#228822">Drugs.com - Clinical Trials</font></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://physicianupdate.mayoclinic.org/2012/05/02/clinical-trials-aid-psc-diagnosis-and-treatment/&amp;ct=ga&amp;cad=CAcQAhgAIAIoATAOOARAw6CF_QRIAVgAYgVlbi1VUw&amp;cd=aTdRJppknhc&amp;usg=AFQjCNGVRJI_kp7IptH-HwYBYSUsdX3gcg" style="color: #1111cc" target="_blank"><strong>Clinical trials</strong> aid PSC diagnosis and treatment | Physician Update</a><br />
<font size="-1"><font color="#777777">By Blog Coordinator</font><br />
Jayant  A. Talwalkar, M.D., a hepatologist with the Department of  Gastroenterology and Hepatology and the Mayo Clinic Transplant Center in  Rochester, Minn., discusses diagnosis, complications, liver  transplantation, and Mayo&#8217;s role in the <strong>&#8230;</strong><br />
<font color="#228822">Physician Update</font></font></td>
</tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" width="600px">
<tr>
<td style="background-color: #ebeff9; padding: 4px 8px">
<table border="0" cellpadding="0" cellspacing="0" width="100%">
<tr>
<td><font size="-1"><strong>Web</strong></font></td>
<td align="right" width="70%"><font size="-1"><strong>2</strong> new results for <strong>clinical trial</strong></font></td>
</tr>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.rawstory.com/rs/2012/05/01/clinical-trials-often-fall-short-u-s-study/&amp;ct=ga&amp;cad=CAcQAhgAIAEoATAPOABAw6CF_QRIAVgAYgVlbi1VUw&amp;cd=aTdRJppknhc&amp;usg=AFQjCNFtc9ahQntAlS9_2Ez8YOJWPeYVnA" style="color: #1111cc" target="_blank"><strong>Clinical trials</strong> often fall short: U.S. study | The Raw Story</a><br />
<font size="-1">That partnership, known as the <strong>Clinical Trials</strong> Transformation Initiative (CTTI), examined more than 96000 studies registered as of September 2010 with the <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://www.rawstory.com/rs/2012/05/01/clinical-trials-often-fall-short-u-s-study/&amp;ct=ga&amp;cad=CAcQAhgAIAEoBDAPOABAw6CF_QRIAVgAYgVlbi1VUw&amp;cd=aTdRJppknhc&amp;usg=AFQjCNFtc9ahQntAlS9_2Ez8YOJWPeYVnA" style="color: #228822" title="http://www.rawstory.com/rs/2012/05/01/clinical-trials-often-fall-short-u-s-study/" target="_blank">www.rawstory.com/rs/&#8230;/<wbr></wbr>clinical-trials-often-fall-<wbr></wbr>short-u-s-stud&#8230;</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px">
<table border="0" cellpadding="0" cellspacing="0" width="100%">
<tr>
<td style="padding: 0px 6px 6px 0px; width: 126px" align="center" valign="top"><a href="http://www.google.com/url?sa=X&amp;q=http://www.newswise.com/articles/clinical-trial-on-promising-ptsd-treatment-technology&amp;ct=ga&amp;cad=CAcQAhgAIAEoAjAQOAFAw6CF_QRIAVgAYgVlbi1VUw&amp;cd=aTdRJppknhc&amp;usg=AFQjCNFv7p0RbWNXxT9ELQYzi6q_G4x9jg" target="_blank"><img height="90" border="0" width="120" /></a></td>
<td valign="top"><a href="http://www.google.com/url?sa=X&amp;q=http://www.newswise.com/articles/clinical-trial-on-promising-ptsd-treatment-technology&amp;ct=ga&amp;cad=CAcQAhgAIAEoATAQOAFAw6CF_QRIAVgAYgVlbi1VUw&amp;cd=aTdRJppknhc&amp;usg=AFQjCNFv7p0RbWNXxT9ELQYzi6q_G4x9jg" style="color: #1111cc" target="_blank"><strong>Clinical Trial</strong> on Promising PTSD Treatment Technology</a><br />
<font size="-1">The study is the first <strong>trial</strong> in the United States, and one of only two <strong>trials</strong> in the world, testing <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://www.newswise.com/articles/clinical-trial-on-promising-ptsd-treatment-technology&amp;ct=ga&amp;cad=CAcQAhgAIAEoBDAQOAFAw6CF_QRIAVgAYgVlbi1VUw&amp;cd=aTdRJppknhc&amp;usg=AFQjCNFv7p0RbWNXxT9ELQYzi6q_G4x9jg" style="color: #228822" title="http://www.newswise.com/articles/clinical-trial-on-promising-ptsd-treatment-technology" target="_blank">www.newswise.com/&#8230;/clinical-<wbr></wbr>trial-on-promising-ptsd-<wbr></wbr>treatme&#8230;</a></font></td>
</tr>
</table>
</td>
</tr>
</table>
]]></content:encoded>
			<wfw:commentRss>http://societyofcollegemedicine.com/2012/05/02/clinical-news-we-are-currently-tracking-2/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Clinical news we are currently tracking&#8230;</title>
		<link>http://societyofcollegemedicine.com/2012/04/30/clinical-news-we-are-currently-tracking/</link>
		<comments>http://societyofcollegemedicine.com/2012/04/30/clinical-news-we-are-currently-tracking/#comments</comments>
		<pubDate>Mon, 30 Apr 2012 19:42:53 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://societyofcollegemedicine.com/2012/04/30/clinical-news-we-are-currently-tracking/</guid>
		<description><![CDATA[




News
9 new results for clinical trial








TKL Research Selects Medidata Solutions&#8217; Clinical Trial Management System to &#8230;
MarketWatch (press release)
NEW YORK, Apr 30, 2012 (BUSINESS WIRE) &#8212; TKL Research, a clinical research organization (CRO), has selected Medidata CTMS(TM), a leading software-as-a-service (SaaS) clinical trial management system offered by Medidata Solutions (NASDAQ:MDSO) &#8230;
See all stories on this topic [...]]]></description>
			<content:encoded><![CDATA[<table width="600px" border="0" cellpadding="0" cellspacing="0">
<tr>
<td style="background-color: #ebeff9; padding: 4px 8px">
<table width="100%" border="0" cellpadding="0" cellspacing="0">
<tr>
<td><font size="-1"><strong>News</strong></font></td>
<td align="right" width="70%"><font size="-1"><strong>9</strong> new results for <strong>clinical trial</strong></font></td>
</tr>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/tkl-research-selects-medidata-solutions-clinical-trial-management-system-to-drive-future-growth-2012-04-30&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAAOABAkt_6_ARIAVAAWABiBWVuLVVT&amp;cd=BbaF8IVzAwg&amp;usg=AFQjCNFv-dp3DLAHT4IdV5Lh4J6neew1ow" style="color: #1111cc" target="_blank">TKL Research Selects Medidata Solutions&#8217; <strong>Clinical Trial</strong> Management System to <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
NEW YORK, Apr 30, 2012 (BUSINESS WIRE) &#8212; TKL Research, a <strong>clinical research</strong> organization (CRO), has selected Medidata CTMS(TM), a leading software-as-a-service (SaaS) <strong>clinical trial</strong> management system offered by Medidata Solutions (NASDAQ:MDSO) <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/tkl-research-selects-medidata-solutions-clinical-trial-management-system-to-drive-future-growth-2012-04-30%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAAOABAkt_6_ARIAVAAWABiBWVuLVVT&amp;cd=BbaF8IVzAwg&amp;usg=AFQjCNEnSV_45TMjZuTwoQiX50HfEmBPrg" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/tkl-research-selects-medidata-solutions-clinical-trial-management-system-to-drive-future-growth-2012-04-30&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://health.usnews.com/health-news/news/articles/2012/04/30/children-usually-excluded-from-clinical-drug-trials-study&amp;ct=ga&amp;cad=CAcQAhgAIAAoATABOAFAkt_6_ARIAVAAWABiBWVuLVVT&amp;cd=BbaF8IVzAwg&amp;usg=AFQjCNFKO3-qYcAItyiW7vfheXmABejthA" style="color: #1111cc" target="_blank">Children Usually Excluded From <strong>Clinical</strong> Drug <strong>Trials</strong>: Study</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">U.S. News &amp; World Report</a><br />
MONDAY, April 30 (HealthDay News) &#8212; Children are more likely than adults to suffer from a number of diseases, but few <strong>clinical trials</strong> are conducted to test new drugs in children with these conditions, researchers have found. In a new study, <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://health.usnews.com/health-news/news/articles/2012/04/30/children-usually-excluded-from-clinical-drug-trials-study%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjABOAFAkt_6_ARIAVAAWABiBWVuLVVT&amp;cd=BbaF8IVzAwg&amp;usg=AFQjCNH282OEwIB7PA8hiKCAqSlhzJ8xLg" style="color: #228822" title="http://news.google.com/news/story?ncl=http://health.usnews.com/health-news/news/articles/2012/04/30/children-usually-excluded-from-clinical-drug-trials-study&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.rtmagazine.com/news/2012-04-30_01.asp&amp;ct=ga&amp;cad=CAcQAhgAIAAoATACOAJAkt_6_ARIAVAAWABiBWVuLVVT&amp;cd=BbaF8IVzAwg&amp;usg=AFQjCNGSXmH3-bBcg8ysNU8lpEcS6GWFIg" style="color: #1111cc" target="_blank"><strong>Clinical Trials</strong> Ignore Pediatric Patients</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">news Stories</a><br />
Although children are more likely than adults to suffer from many diseases, few <strong>clinical trials</strong>  are being conducted to test drugs in pediatric patients, according to a  study presented at the Pediatric Academic Societies annual meeting in  Boston.<br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.rtmagazine.com/news/2012-04-30_01.asp%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjACOAJAkt_6_ARIAVAAWABiBWVuLVVT&amp;cd=BbaF8IVzAwg&amp;usg=AFQjCNGUVWqRydDpFAOAi5Ol3IzkT4S3Jg" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.rtmagazine.com/news/2012-04-30_01.asp&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/syndax-pharmaceuticals-announces-publication-of-entinostat-phase-2-clinical-trial-data-in-journal-of-clinical-oncology-2012-04-30&amp;ct=ga&amp;cad=CAcQAhgAIAAoATADOANAkt_6_ARIAVAAWABiBWVuLVVT&amp;cd=BbaF8IVzAwg&amp;usg=AFQjCNHQ43_mEBufYtNs_Kp6nWaLoc6nzQ" style="color: #1111cc" target="_blank">Syndax Pharmaceuticals Announces Publication of Entinostat Phase 2 <strong>Clinical</strong> <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
Of course, further <strong>studies</strong>  in both of these groups of patients will be necessary to confirm these  observations.&#8221; &#8220;The data published in JCO adds to the growing body of <strong>clinical</strong> data supporting the promise for entinostat and our continued development of <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/syndax-pharmaceuticals-announces-publication-of-entinostat-phase-2-clinical-trial-data-in-journal-of-clinical-oncology-2012-04-30%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjADOANAkt_6_ARIAVAAWABiBWVuLVVT&amp;cd=BbaF8IVzAwg&amp;usg=AFQjCNG5bw8gPewTov1Yd8L43B38HKVtdQ" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/syndax-pharmaceuticals-announces-publication-of-entinostat-phase-2-clinical-trial-data-in-journal-of-clinical-oncology-2012-04-30&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/altor-bioscience-and-the-melanoma-research-alliance-to-co-support-clinical-studies-of-altors-novel-il-15-superagonist-for-metastatic-melanoma-2012-04-30&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAEOARAkt_6_ARIAVAAWABiBWVuLVVT&amp;cd=BbaF8IVzAwg&amp;usg=AFQjCNH6q4QNX7fXS2CV8PeqpZyIhBIs7A" style="color: #1111cc" target="_blank">Altor BioScience and the Melanoma <strong>Research</strong> Alliance to Co-Support <strong>Clinical</strong> <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
MRA&#8217;s grant, in conjunction with Altor&#8217;s support, will allow Dr. Margolis to conduct a first-in-human safety and efficacy <strong>clinical trial</strong> of ALT-803 in patients with incurable melanoma. The project will also include research studies on the effects of <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/altor-bioscience-and-the-melanoma-research-alliance-to-co-support-clinical-studies-of-altors-novel-il-15-superagonist-for-metastatic-melanoma-2012-04-30%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAEOARAkt_6_ARIAVAAWABiBWVuLVVT&amp;cd=BbaF8IVzAwg&amp;usg=AFQjCNEyVPArR1WgsH8A7rHBHe5QAfpYyA" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/altor-bioscience-and-the-melanoma-research-alliance-to-co-support-clinical-studies-of-altors-novel-il-15-superagonist-for-metastatic-melanoma-2012-04-30&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.timesunion.com/business/press-releases/article/CNS-Network-Partners-With-Verified-Clinical-3520405.php&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAFOAVAkt_6_ARIAVAAWABiBWVuLVVT&amp;cd=BbaF8IVzAwg&amp;usg=AFQjCNGD5TLbzWS47TXItSYX89Zniac4RA" style="color: #1111cc" target="_blank">CNS Network Partners With Verified <strong>Clinical Trials</strong> And Joins The VCT National <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">Albany Times Union</a><br />
CNS Network, a leader in CNS <strong>clinical trial</strong> research selects Verified <strong>Clinical Trials</strong> (VCT) national <strong>clinical trial</strong> database registry to stop attempted dual enrollment in <strong>clinical trial</strong> research. Verified <strong>Clinical Trials</strong> has the largest North American <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.timesunion.com/business/press-releases/article/CNS-Network-Partners-With-Verified-Clinical-3520405.php%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAFOAVAkt_6_ARIAVAAWABiBWVuLVVT&amp;cd=BbaF8IVzAwg&amp;usg=AFQjCNFrJ0ziAxdsdOp3JsyC8ZlHtwI6zw" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.timesunion.com/business/press-releases/article/CNS-Network-Partners-With-Verified-Clinical-3520405.php&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/cleveland-biolabs-and-incuron-announce-russian-regulatory-allowance-of-ind-for-phase-1b-trial-of-cblc137-2012-04-30&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAGOAZAkt_6_ARIAVAAWABiBWVuLVVT&amp;cd=BbaF8IVzAwg&amp;usg=AFQjCNHXB3W22vVT-s7QA96El4T5mw1nIA" style="color: #1111cc" target="_blank">Cleveland BioLabs and Incuron Announce Russian Regulatory Allowance of IND for <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
Andrey Leonov, Chief Executive Officer of Incuron, LLC, commented, &#8220;We are excited to start <strong>clinical trials</strong>  with CBLC137, a proprietary new molecular entity. This initial trial is  expected to generate valuable input on the future development of  CBLC137 <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/cleveland-biolabs-and-incuron-announce-russian-regulatory-allowance-of-ind-for-phase-1b-trial-of-cblc137-2012-04-30%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAGOAZAkt_6_ARIAVAAWABiBWVuLVVT&amp;cd=BbaF8IVzAwg&amp;usg=AFQjCNHjjxg1AtFh-WYnxkc1mor2aUE-XA" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/cleveland-biolabs-and-incuron-announce-russian-regulatory-allowance-of-ind-for-phase-1b-trial-of-cblc137-2012-04-30&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.prweb.com/releases/clinical_trials/CTMS_market/prweb9456959.htm&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAHOAdAkt_6_ARIAVAAWABiBWVuLVVT&amp;cd=BbaF8IVzAwg&amp;usg=AFQjCNE2W3cbo_LTZhlRuj0AX6W5ufYMmA" style="color: #1111cc" target="_blank">Efforts to Curtail Drug Development Costs to Drive the Global <strong>Clinical Trial</strong> <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">PR Web (press release)</a><br />
GIA announces the release of a comprehensive global report on <strong>Clinical Trial</strong> Management Systems (CTMS) market. The global market for <strong>Clinical Trial</strong> Management Systems (CTMS) is forecast to reach US$1.76 billion by the year 2017, driven by the need <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.prweb.com/releases/clinical_trials/CTMS_market/prweb9456959.htm%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAHOAdAkt_6_ARIAVAAWABiBWVuLVVT&amp;cd=BbaF8IVzAwg&amp;usg=AFQjCNE0_CvjJxV1S7CLDzdlaO0HpY4QeQ" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.prweb.com/releases/clinical_trials/CTMS_market/prweb9456959.htm&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/ventrus-biosciences-completes-enrollment-of-pivotal-phase-3-trial-of-iferanserin-ven-309-in-patients-with-hemorrhoidal-disease-2012-04-30&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAIOAhAkt_6_ARIAVAAWABiBWVuLVVT&amp;cd=BbaF8IVzAwg&amp;usg=AFQjCNG0Qi719hq2KPexOHWZtkCxixJB1g" style="color: #1111cc" target="_blank">Ventrus Biosciences Completes Enrollment of Pivotal Phase 3 <strong>Trial</strong> of <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
NEW  YORK, Apr 30, 2012 (GlobeNewswire via COMTEX) &#8212; Ventrus Biosciences,  Inc. (UTD:VTUS) announced that it has completed patient enrollment and  randomization in the first Phase 3 <strong>clinical trial</strong> of iferanserin (VEN 309) in patients with grade 1-3 <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/ventrus-biosciences-completes-enrollment-of-pivotal-phase-3-trial-of-iferanserin-ven-309-in-patients-with-hemorrhoidal-disease-2012-04-30%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAIOAhAkt_6_ARIAVAAWABiBWVuLVVT&amp;cd=BbaF8IVzAwg&amp;usg=AFQjCNFsJOmSewat1NnvURae9jJHJ8JM-g" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/ventrus-biosciences-completes-enrollment-of-pivotal-phase-3-trial-of-iferanserin-ven-309-in-patients-with-hemorrhoidal-disease-2012-04-30&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
</table>
<table width="600px" border="0" cellpadding="0" cellspacing="0">
<tr>
<td style="background-color: #ebeff9; padding: 4px 8px">
<table width="100%" border="0" cellpadding="0" cellspacing="0">
<tr>
<td><font size="-1"><strong>Blogs</strong></font></td>
<td align="right" width="70%"><font size="-1"><strong>3</strong> new results for <strong>clinical trial</strong></font></td>
</tr>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.ivillage.com/children-usually-excluded-clinical-drug-trials-study/4-a-449433&amp;ct=ga&amp;cad=CAcQAhgAIAIoATAJOABAkt_6_ARIAVgAYgVlbi1VUw&amp;cd=BbaF8IVzAwg&amp;usg=AFQjCNEyH_SQHPCM4-0la3kIA3O4jTTd9w" style="color: #1111cc" target="_blank">Children Usually Excluded From <strong>Clinical</strong> Drug <strong>Trials</strong>: Study - iVillage</a><br />
<font size="-1"><font color="#777777">By HealthDay</font><br />
MONDAY, April 30 (HealthDay News) &#8212; Children are more likely than adults to suffer from a number of diseases, but few <em>clinical trials</em> are conducted to test new drugs in children with these conditions, researchers have found. In a new study, r.<br />
<font color="#228822">Health - iVillage</font></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.ncpa.org/sub/dpd/index.php%3FArticle_ID%3D21867&amp;ct=ga&amp;cad=CAcQAhgAIAIoATAKOAFAkt_6_ARIAVgAYgVlbi1VUw&amp;cd=BbaF8IVzAwg&amp;usg=AFQjCNHo9A8NOTPD7DZg0-CZiiRMt2RQSg" style="color: #1111cc" target="_blank">Stifling New Cures: The True Cost of Lengthy <strong>Clinical</strong> Drug <strong>Trials</strong></a><br />
<font size="-1">The enormous cost and risk of Phase III <em>trials</em>  create incentives for researchers and investors to avoid work on  medications for the chronic conditions and illnesses that pose the  greatest threat to Americans&#8230;<br />
<font color="#228822">Daily Policy Digest</font></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.drugs.com/clinical_trials/ampio-pharmaceuticals-announces-extended-analysis-ampion-knee-aik-study-shows-pain-relief-13419.html&amp;ct=ga&amp;cad=CAcQAhgAIAIoATALOAJAkt_6_ARIAVgAYgVlbi1VUw&amp;cd=BbaF8IVzAwg&amp;usg=AFQjCNHFTkihMCVmdl223R_a7vwNkx9Heg" style="color: #1111cc" target="_blank">Ampio Pharmaceuticals announces extended analysis of Ampion In <strong>&#8230;</strong></a><br />
<font size="-1">Ampio Pharmaceuticals, Inc. (Nasdaq AMPE), a biopharmaceutical company conducting <em>clinical trials</em> on its three lead drugs (Ampion , Optina and Zertane ), licens.<br />
<font color="#228822">Drugs.com - Clinical Trials</font></font></td>
</tr>
</table>
<table width="600px" border="0" cellpadding="0" cellspacing="0">
<tr>
<td style="background-color: #ebeff9; padding: 4px 8px">
<table width="100%" border="0" cellpadding="0" cellspacing="0">
<tr>
<td><font size="-1"><strong>Web</strong></font></td>
<td align="right" width="70%"><font size="-1"><strong>4</strong> new results for <strong>clinical trial</strong></font></td>
</tr>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.nejm.org/doi/full/10.1056/NEJMoa1109333&amp;ct=ga&amp;cad=CAcQAhgAIAEoATAMOABAkt_6_ARIAVgAYgVlbi1VUw&amp;cd=BbaF8IVzAwg&amp;usg=AFQjCNGAJG8qRf_0fe8sklM1bHe09sdBFg" style="color: #1111cc" target="_blank">A <strong>Clinical Trial</strong> to Maintain Glycemic Control in Youth with Type 2 <strong>&#8230;</strong></a><br />
<font size="-1">Original Article from The New England Journal of Medicine — A <strong>Clinical Trial</strong> to Maintain Glycemic Control in Youth with Type 2 Diabetes.<br />
<a href="http://www.google.com/url?sa=X&amp;q=http://www.nejm.org/doi/full/10.1056/NEJMoa1109333&amp;ct=ga&amp;cad=CAcQAhgAIAEoBDAMOABAkt_6_ARIAVgAYgVlbi1VUw&amp;cd=BbaF8IVzAwg&amp;usg=AFQjCNGAJG8qRf_0fe8sklM1bHe09sdBFg" style="color: #228822" title="http://www.nejm.org/doi/full/10.1056/NEJMoa1109333" target="_blank">www.nejm.org/doi/full/10.1056/<wbr></wbr>NEJMoa1109333</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.alsa.org/news/archive/rfa-clinical-research.html&amp;ct=ga&amp;cad=CAcQAhgAIAEoATANOAFAkt_6_ARIAVgAYgVlbi1VUw&amp;cd=BbaF8IVzAwg&amp;usg=AFQjCNHBz_N7887utziD72gD_aiW5RwWPg" style="color: #1111cc" target="_blank"><strong>Clinical Research</strong> Pilot Study Request for Proposals - The ALS <strong>&#8230;</strong></a><br />
<font size="-1">This request for proposals (RFP) seeks to fund pilot <strong>clinical studies</strong> to obtain preliminary clinical data which will support applications to the National Institutes of <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://www.alsa.org/news/archive/rfa-clinical-research.html&amp;ct=ga&amp;cad=CAcQAhgAIAEoBDANOAFAkt_6_ARIAVgAYgVlbi1VUw&amp;cd=BbaF8IVzAwg&amp;usg=AFQjCNHBz_N7887utziD72gD_aiW5RwWPg" style="color: #228822" title="http://www.alsa.org/news/archive/rfa-clinical-research.html" target="_blank">www.alsa.org/news/archive/rfa-<wbr></wbr>clinical-research.html</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.jeffersonhospital.org/The-Daily-Dose/2012/April/cancer-clinical-trials-at-jefferson.aspx&amp;ct=ga&amp;cad=CAcQAhgAIAEoATAOOAJAkt_6_ARIAVgAYgVlbi1VUw&amp;cd=BbaF8IVzAwg&amp;usg=AFQjCNFUaDun8MqrmPZf3VbWIddogFGNbQ" style="color: #1111cc" target="_blank">Cancer <strong>Clinical Trials</strong> at Jefferson - Thomas Jefferson University <strong>&#8230;</strong></a><br />
<font size="-1"><strong>Clinical trials</strong>  are a key method to improve prevention, screening, diagnosis and  treatment of cancer, so it is important that patients who consider  understand the <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://www.jeffersonhospital.org/The-Daily-Dose/2012/April/cancer-clinical-trials-at-jefferson.aspx&amp;ct=ga&amp;cad=CAcQAhgAIAEoBDAOOAJAkt_6_ARIAVgAYgVlbi1VUw&amp;cd=BbaF8IVzAwg&amp;usg=AFQjCNFUaDun8MqrmPZf3VbWIddogFGNbQ" style="color: #228822" title="http://www.jeffersonhospital.org/The-Daily-Dose/2012/April/cancer-clinical-trials-at-jefferson.aspx" target="_blank">www.jeffersonhospital.org/&#8230;/<wbr></wbr>cancer-clinical-trials-at-<wbr></wbr>jefferson&#8230;.</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.azcentral.com/arizonarepublic/business/articles/2012/04/26/20120426firm-aid-small-practices-clinical-trials.html&amp;ct=ga&amp;cad=CAcQAhgAIAEoATAPOANAkt_6_ARIAVgAYgVlbi1VUw&amp;cd=BbaF8IVzAwg&amp;usg=AFQjCNEIfkPnGPWryY1rhARbeCyqAakn3w" style="color: #1111cc" target="_blank">Firm to aid small practices&#8217; <strong>clinical trials</strong></a><br />
<font size="-1">Firm to aid small practices&#8217; <strong>clinical trials</strong>, Arizona hospitals have committed more than $400 million on new cancer centers and technology in an effort to bring the <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://www.azcentral.com/arizonarepublic/business/articles/2012/04/26/20120426firm-aid-small-practices-clinical-trials.html&amp;ct=ga&amp;cad=CAcQAhgAIAEoBDAPOANAkt_6_ARIAVgAYgVlbi1VUw&amp;cd=BbaF8IVzAwg&amp;usg=AFQjCNEIfkPnGPWryY1rhARbeCyqAakn3w" style="color: #228822" title="http://www.azcentral.com/arizonarepublic/business/articles/2012/04/26/20120426firm-aid-small-practices-clinical-trials.html" target="_blank">www.azcentral.com/&#8230;/<wbr></wbr>20120426firm-aid-small-<wbr></wbr>practices-clini&#8230;</a></font></td>
</tr>
</table>
]]></content:encoded>
			<wfw:commentRss>http://societyofcollegemedicine.com/2012/04/30/clinical-news-we-are-currently-tracking/feed/</wfw:commentRss>
		</item>
		<item>
		<title>News we are currently tracking&#8230;</title>
		<link>http://societyofcollegemedicine.com/2012/04/26/news-we-are-currently-tracking-9/</link>
		<comments>http://societyofcollegemedicine.com/2012/04/26/news-we-are-currently-tracking-9/#comments</comments>
		<pubDate>Thu, 26 Apr 2012 00:25:15 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://societyofcollegemedicine.com/2012/04/26/news-we-are-currently-tracking-9/</guid>
		<description><![CDATA[




News
9 new results for clinical trial








PRC Clinical Selects SimpleCTMS Clinical Trial Management System
MarketWatch (press release)
OAKLAND, CA, Apr 25, 2012 (MARKETWIRE via COMTEX) &#8212; Trial By Fire Solutions, a leading eClinical solution provider specializing in clinical study management applications, today announced that PRC Clinical, a privately held Contract Research &#8230;
See all stories on this topic »





How [...]]]></description>
			<content:encoded><![CDATA[<table width="600px" border="0" cellpadding="0" cellspacing="0">
<tr>
<td style="background-color: #ebeff9; padding: 4px 8px">
<table width="100%" border="0" cellpadding="0" cellspacing="0">
<tr>
<td><font size="-1"><strong>News</strong></font></td>
<td align="right" width="70%"><font size="-1"><strong>9</strong> new results for <strong>clinical trial</strong></font></td>
</tr>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/prc-clinical-selects-simplectms-clinical-trial-management-system-2012-04-25&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAAOABAp7Dg_ARIAVAAWABiBWVuLVVT&amp;cd=jLrmmgs0gqI&amp;usg=AFQjCNGFKCZnQlyt4cAuxO8mnuWpHI6XKA" style="color: #1111cc" target="_blank">PRC Clinical Selects SimpleCTMS <strong>Clinical Trial</strong> Management System</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
OAKLAND, CA, Apr 25, 2012 (MARKETWIRE via COMTEX) &#8212; <strong>Trial</strong> By Fire Solutions, a leading eClinical solution provider specializing in <strong>clinical</strong> study management applications, today announced that PRC <strong>Clinical</strong>, a privately held Contract <strong>Research</strong> <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/prc-clinical-selects-simplectms-clinical-trial-management-system-2012-04-25%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAAOABAp7Dg_ARIAVAAWABiBWVuLVVT&amp;cd=jLrmmgs0gqI&amp;usg=AFQjCNHZ8enH2wrKke8dUcf3pknquHgoHw" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/prc-clinical-selects-simplectms-clinical-trial-management-system-2012-04-25&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px">
<table width="100%" border="0" cellpadding="0" cellspacing="0">
<tr>
<td valign="top"><a href="http://www.google.com/url?sa=X&amp;q=http://www.forbes.com/sites/aroy/2012/04/25/how-the-fda-stifles-new-cures-part-ii-90-of-clinical-trial-costs-are-incurred-in-phase-iii/&amp;ct=ga&amp;cad=CAcQAhgAIAAoATABOAFAp7Dg_ARIAVAAWABiBWVuLVVT&amp;cd=jLrmmgs0gqI&amp;usg=AFQjCNGiEIuDEaejLtLOqEtqyJOzTxr3AQ" style="color: #1111cc" target="_blank">How the FDA Stifles New Cures, Part II: 90% of <strong>Clinical Trial</strong> Costs are <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">Forbes</a><br />
&#8220;Stifling New Cures: The True Cost of Lengthy <strong>Clinical Trials</strong>,&#8221;  by Avik Roy. Yesterday, the Manhattan Institute released a study I  authored, entitled “Stifling New Cures: The True Cost of Lengthy  Clinical Drug Trials.” (You can read the full report <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.forbes.com/sites/aroy/2012/04/25/how-the-fda-stifles-new-cures-part-ii-90-of-clinical-trial-costs-are-incurred-in-phase-iii/%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjABOAFAp7Dg_ARIAVAAWABiBWVuLVVT&amp;cd=jLrmmgs0gqI&amp;usg=AFQjCNHtUMumgQbtHdugESLH5ARysoWXXA" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.forbes.com/sites/aroy/2012/04/25/how-the-fda-stifles-new-cures-part-ii-90-of-clinical-trial-costs-are-incurred-in-phase-iii/&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
<td align="center" valign="top" width="80"><a href="http://www.google.com/url?sa=X&amp;q=http://www.forbes.com/sites/aroy/2012/04/25/how-the-fda-stifles-new-cures-part-ii-90-of-clinical-trial-costs-are-incurred-in-phase-iii/&amp;ct=ga&amp;cad=CAcQAhgAIAAoAjABOAFAp7Dg_ARIAVAAWABiBWVuLVVT&amp;cd=jLrmmgs0gqI&amp;usg=AFQjCNGiEIuDEaejLtLOqEtqyJOzTxr3AQ" target="_blank"><img height="38" width="80" border="0" /></a><font size="-2"><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://www.forbes.com/sites/aroy/2012/04/25/how-the-fda-stifles-new-cures-part-ii-90-of-clinical-trial-costs-are-incurred-in-phase-iii/&amp;ct=ga&amp;cad=CAcQAhgAIAAoAzABOAFAp7Dg_ARIAVAAWABiBWVuLVVT&amp;cd=jLrmmgs0gqI&amp;usg=AFQjCNGiEIuDEaejLtLOqEtqyJOzTxr3AQ" target="_blank">Forbes</a></font></td>
</tr>
</table>
</td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/atheronova-signs-agreement-for-development-of-clinical-trial-supplies-2012-04-25&amp;ct=ga&amp;cad=CAcQAhgAIAAoATACOAJAp7Dg_ARIAVAAWABiBWVuLVVT&amp;cd=jLrmmgs0gqI&amp;usg=AFQjCNF4CS9OmrCxbwE5YKLbz5qeLdsDHQ" style="color: #1111cc" target="_blank">AtheroNova Signs Agreement for Development of <strong>Clinical Trial</strong> Supplies</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
Frontage CEO, Dr. Song Li, also commented on the agreement, stating &#8220;It is an honor to work with AtheroNova on this vital <strong>clinical trial</strong> materials project. Frontage&#8217;s 10-year history of delivering pharmaceutical R&amp;D services in a fast and efficient <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/atheronova-signs-agreement-for-development-of-clinical-trial-supplies-2012-04-25%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjACOAJAp7Dg_ARIAVAAWABiBWVuLVVT&amp;cd=jLrmmgs0gqI&amp;usg=AFQjCNGZZDYZxdsACZT0iEW0ZEpQbethTA" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/atheronova-signs-agreement-for-development-of-clinical-trial-supplies-2012-04-25&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/repligen-reports-positive-results-from-phase-1-clinical-trial-of-rg3039-for-spinal-muscular-atrophy-2012-04-25&amp;ct=ga&amp;cad=CAcQAhgAIAAoATADOANAp7Dg_ARIAVAAWABiBWVuLVVT&amp;cd=jLrmmgs0gqI&amp;usg=AFQjCNGU9fA6bKgv3DHsjCuCNlCONsOaAw" style="color: #1111cc" target="_blank">Repligen Reports Positive Results from Phase 1 <strong>Clinical Trial</strong> of RG3039 for <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
In addition to the Phase 1 <strong>clinical trial</strong>  outcomes, the AAN presentation highlights the results of earlier mouse  model studies conducted with RG3039 at Johns Hopkins University and in  the lab of Dr. Chien-Ping Ko at University of Southern California.<br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/repligen-reports-positive-results-from-phase-1-clinical-trial-of-rg3039-for-spinal-muscular-atrophy-2012-04-25%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjADOANAp7Dg_ARIAVAAWABiBWVuLVVT&amp;cd=jLrmmgs0gqI&amp;usg=AFQjCNH_mnu8_kFMdB6W3QoykGMOAebvwA" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/repligen-reports-positive-results-from-phase-1-clinical-trial-of-rg3039-for-spinal-muscular-atrophy-2012-04-25&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/repligen-reports-positive-results-from-phase-1-clinical-trial-for-spinal-muscular-atrophy-sma-2012-04-25&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAEOARAp7Dg_ARIAVAAWABiBWVuLVVT&amp;cd=jLrmmgs0gqI&amp;usg=AFQjCNEQp__D3ncTceyYSGIh8hJPp0CTUg" style="color: #1111cc" target="_blank">Repligen Reports Positive Results From Phase 1 <strong>Clinical Trial</strong> for Spinal <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
Repligen&#8217;s <strong>research</strong>  efforts including this Phase 1 study have been partially supported by a  grant from the Muscular Dystrophy Association (MDA). RG3039 is the  first <strong>clinical</strong>-stage drug candidate to target the core genetic deficit in SMA in order to <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/repligen-reports-positive-results-from-phase-1-clinical-trial-for-spinal-muscular-atrophy-sma-2012-04-25%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAEOARAp7Dg_ARIAVAAWABiBWVuLVVT&amp;cd=jLrmmgs0gqI&amp;usg=AFQjCNE9qk3alPhuEP4iQ4RGHdWEk3nVbQ" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/repligen-reports-positive-results-from-phase-1-clinical-trial-for-spinal-muscular-atrophy-sma-2012-04-25&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/centerwatch-launches-online-data-library-of-the-clinical-research-industry-2012-04-25&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAFOAVAp7Dg_ARIAVAAWABiBWVuLVVT&amp;cd=jLrmmgs0gqI&amp;usg=AFQjCNGJGO_TZodyPFav1nQRNHtKbVma1A" style="color: #1111cc" target="_blank">CenterWatch launches online data library of the <strong>clinical research</strong> industry</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
BOSTON, Apr 25, 2012 (BUSINESS WIRE) &#8212; CenterWatch, a leading provider of business information and market intelligence on the <strong>clinical research</strong> industry, announced today the release of its new online Data Library. The online resource features hundreds <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/centerwatch-launches-online-data-library-of-the-clinical-research-industry-2012-04-25%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAFOAVAp7Dg_ARIAVAAWABiBWVuLVVT&amp;cd=jLrmmgs0gqI&amp;usg=AFQjCNHUgtSbL3k7L9WXJTfcf4o6du3sFg" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/centerwatch-launches-online-data-library-of-the-clinical-research-industry-2012-04-25&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/repligen-announces-favorable-results-from-phase-1-clinical-trial-of-experimental-treatment-for-spinal-muscular-atrophy-2012-04-25&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAGOAZAp7Dg_ARIAVAAWABiBWVuLVVT&amp;cd=jLrmmgs0gqI&amp;usg=AFQjCNFWdFUHr0PXFR-WugGII4AEA0jZeQ" style="color: #1111cc" target="_blank">Repligen Announces Favorable Results from Phase 1 <strong>Clinical Trial</strong> of <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
TUCSON,  Ariz., April 25, 2012 /PRNewswire via COMTEX/ &#8212; Repligen Corp., in  Waltham, Mass., announced today that its experimental drug RG3039,  designed to treat spinal muscular atrophy (SMA), was safe and  well-tolerated in a phase 1 <strong>clinical trial</strong>.<br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/repligen-announces-favorable-results-from-phase-1-clinical-trial-of-experimental-treatment-for-spinal-muscular-atrophy-2012-04-25%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAGOAZAp7Dg_ARIAVAAWABiBWVuLVVT&amp;cd=jLrmmgs0gqI&amp;usg=AFQjCNHA7SupQjU4y9-CSYFgsrktbvywag" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/repligen-announces-favorable-results-from-phase-1-clinical-trial-of-experimental-treatment-for-spinal-muscular-atrophy-2012-04-25&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.sacbee.com/2012/04/25/4440528/repligen-announces-favorable-results.html&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAHOAdAp7Dg_ARIAVAAWABiBWVuLVVT&amp;cd=jLrmmgs0gqI&amp;usg=AFQjCNHb8sc7_YQLTTEETnHiACxq1E7emQ" style="color: #1111cc" target="_blank">Repligen Announces Favorable Results from Phase 1 <strong>Clinical Trial</strong> of <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">Sacramento Bee</a><br />
MDA awarded Repligen $1.4 million in December 2010 to support the advancement of RG3039 into phase 1 <strong>clinical trials</strong>. The award was made through MDA Venture Philanthropy (MVP), the drug development arm of MDA&#8217;s translational research program.<br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.sacbee.com/2012/04/25/4440528/repligen-announces-favorable-results.html%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAHOAdAp7Dg_ARIAVAAWABiBWVuLVVT&amp;cd=jLrmmgs0gqI&amp;usg=AFQjCNFvTOckrqUKe1LEU-UlpF0ZgBw4FQ" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.sacbee.com/2012/04/25/4440528/repligen-announces-favorable-results.html&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/nanobody-for-alzheimers-disease-from-the-alliance-with-boehringer-ingelheim-moves-closer-towards-phase-i-clinical-trials-2012-04-25-57200&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAIOAhAp7Dg_ARIAVAAWABiBWVuLVVT&amp;cd=jLrmmgs0gqI&amp;usg=AFQjCNEcrI_SqK5u9sIYZjoBkEgaNRsy-Q" style="color: #1111cc" target="_blank">NANOBODY FOR ALZHEIMER&#8217;S DISEASE FROM THE ALLIANCE WITH BOEHRINGER INGELHEIM <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
GHENT, Belgium, 25 April 2012 - Ablynx [Euronext Brussels: ABLX] today announced that Boehringer Ingelheim has submitted a <strong>Clinical Trials</strong> Application (CTA) to the European regulatory authorities to start a Phase I <strong>clinical trial</strong> with a Nanobody® for <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/nanobody-for-alzheimers-disease-from-the-alliance-with-boehringer-ingelheim-moves-closer-towards-phase-i-clinical-trials-2012-04-25-57200%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAIOAhAp7Dg_ARIAVAAWABiBWVuLVVT&amp;cd=jLrmmgs0gqI&amp;usg=AFQjCNHWrnLGVOhFYOZdAjcayXj3keDjZQ" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/nanobody-for-alzheimers-disease-from-the-alliance-with-boehringer-ingelheim-moves-closer-towards-phase-i-clinical-trials-2012-04-25-57200&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
</table>
<table width="600px" border="0" cellpadding="0" cellspacing="0">
<tr>
<td style="background-color: #ebeff9; padding: 4px 8px">
<table width="100%" border="0" cellpadding="0" cellspacing="0">
<tr>
<td><font size="-1"><strong>Blogs</strong></font></td>
<td align="right" width="70%"><font size="-1"><strong>2</strong> new results for <strong>clinical trial</strong></font></td>
</tr>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.drugs.com/clinical_trials/repligen-reports-positive-results-phase-1-clinical-trial-rg3039-spinal-muscular-atrophy-13395.html&amp;ct=ga&amp;cad=CAcQAhgAIAIoATAJOABAp7Dg_ARIAVgAYgVlbi1VUw&amp;cd=jLrmmgs0gqI&amp;usg=AFQjCNHPm4l-FhXkIpIMQzYjYVN92zNqag" style="color: #1111cc" target="_blank">Repligen Reports Positive Results from Phase 1 <strong>Clinical Trial</strong> of <strong>&#8230;</strong></a><br />
<font size="-1">Apr  25, 2012 - Repligen Corporation (NASDAQ RGEN) today announced positive  results from a Phase 1 study to evaluate the pharmacokinetic (PK) and  safety profile.<br />
<font color="#228822">Drugs.com - Clinical Trials</font></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.xconomy.com/san-francisco/2012/04/24/ims-health-buys-decisionview-for-programs-to-speed-clinical-trials/&amp;ct=ga&amp;cad=CAcQAhgAIAIoATAKOAFAp7Dg_ARIAVgAYgVlbi1VUw&amp;cd=jLrmmgs0gqI&amp;usg=AFQjCNEb1BWj2ZD3F1y0m0t5vLgmF6ajYg" style="color: #1111cc" target="_blank">IMS Health Buys DecisionView For Programs to Speed <strong>Clinical Trials</strong></a><br />
<font size="-1"><font color="#777777">By Luke Timmerman</font><br />
IMS  Health, the giant healthcare market information company based in  Danbury, CT, said today it is acquiring San Francisco-based DecisionView  for an undisclosed.<br />
<font color="#228822">Xconomy</font></font></td>
</tr>
</table>
<table width="600px" border="0" cellpadding="0" cellspacing="0">
<tr>
<td style="background-color: #ebeff9; padding: 4px 8px">
<table width="100%" border="0" cellpadding="0" cellspacing="0">
<tr>
<td><font size="-1"><strong>Web</strong></font></td>
<td align="right" width="70%"><font size="-1"><strong>1</strong> new result for <strong>clinical trial</strong></font></td>
</tr>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.phrma.org/catalyst/match-making-clinical-trial-services-help-spread-the-word-to-patients&amp;ct=ga&amp;cad=CAcQAhgAIAEoATALOABAp7Dg_ARIAVgAYgVlbi1VUw&amp;cd=jLrmmgs0gqI&amp;usg=AFQjCNF4rjLs1KhS6l84bhEe5oVFwoiQUA" style="color: #1111cc" target="_blank">“Match-Making” <strong>Clinical Trial</strong> Services Help Spread the Word to <strong>&#8230;</strong></a><br />
<font size="-1">This  morning, my colleague Sharon Brigner alerted me to an article in the  Wall Street Journal (subscription required) about some efforts by  patient advocacy <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://www.phrma.org/catalyst/match-making-clinical-trial-services-help-spread-the-word-to-patients&amp;ct=ga&amp;cad=CAcQAhgAIAEoBDALOABAp7Dg_ARIAVgAYgVlbi1VUw&amp;cd=jLrmmgs0gqI&amp;usg=AFQjCNF4rjLs1KhS6l84bhEe5oVFwoiQUA" style="color: #228822" title="http://www.phrma.org/catalyst/match-making-clinical-trial-services-help-spread-the-word-to-patients" target="_blank">www.phrma.org/&#8230;/match-<wbr></wbr>making-clinical-trial-<wbr></wbr>services-help-s&#8230;</a></font></td>
</tr>
</table>
]]></content:encoded>
			<wfw:commentRss>http://societyofcollegemedicine.com/2012/04/26/news-we-are-currently-tracking-9/feed/</wfw:commentRss>
		</item>
		<item>
		<title>News we are currently Tracking&#8230;</title>
		<link>http://societyofcollegemedicine.com/2012/04/09/news-we-are-currently-tracking-8/</link>
		<comments>http://societyofcollegemedicine.com/2012/04/09/news-we-are-currently-tracking-8/#comments</comments>
		<pubDate>Mon, 09 Apr 2012 18:46:55 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://societyofcollegemedicine.com/2012/04/09/news-we-are-currently-tracking-8/</guid>
		<description><![CDATA[




News









Mytrus Rolls Out Clinical Research Industry&#8217;s First Patient-Friendly System &#8230;
MarketWatch (press release)
Using  animation and other visual imagery, the Mytrus iPad application is the  first in the industry to condense the complex and critical disclosure  information required at the start of a clinical trial into an easy-to-understand, digitized format.
See all stories on this [...]]]></description>
			<content:encoded><![CDATA[<table border="0" cellpadding="0" cellspacing="0" width="600px">
<tr>
<td style="background-color: #ebeff9; padding: 4px 8px">
<table border="0" cellpadding="0" cellspacing="0" width="100%">
<tr>
<td><font size="-1"><strong>News</strong></font></td>
<td align="right" width="70%"><font size="-1"></font></td>
</tr>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/mytrus-rolls-out-clinical-research-industrys-first-patient-friendly-system-for-informed-consent-via-ipadr-application-2012-04-09&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAAOABA1vuL_ARIAVAAWABiBWVuLVVT&amp;cd=NTONxdq1Qm0&amp;usg=AFQjCNEPVP0oNiqvt97Xj0FgO5rNe95_Mw" style="color: #1111cc" target="_blank">Mytrus Rolls Out <strong>Clinical Research</strong> Industry&#8217;s First Patient-Friendly System <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
Using  animation and other visual imagery, the Mytrus iPad application is the  first in the industry to condense the complex and critical disclosure  information required at the start of a <strong>clinical trial</strong> into an easy-to-understand, digitized format.<br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/mytrus-rolls-out-clinical-research-industrys-first-patient-friendly-system-for-informed-consent-via-ipadr-application-2012-04-09%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAAOABA1vuL_ARIAVAAWABiBWVuLVVT&amp;cd=NTONxdq1Qm0&amp;usg=AFQjCNFHsdvaRKW65GXVGWeMt3QsD5R6eg" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/mytrus-rolls-out-clinical-research-industrys-first-patient-friendly-system-for-informed-consent-via-ipadr-application-2012-04-09&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/stealth-peptides-inc-reports-results-from-phase-i-clinical-drug-interaction-studies-with-bendavia-2012-04-09&amp;ct=ga&amp;cad=CAcQAhgAIAAoATABOAFA1vuL_ARIAVAAWABiBWVuLVVT&amp;cd=NTONxdq1Qm0&amp;usg=AFQjCNFKdDMFdcHxrjXcltKtknHN6UoioA" style="color: #1111cc" target="_blank">Stealth Peptides Inc. Reports Results from Phase I <strong>Clinical</strong> Drug Interaction <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
BOSTON,  Apr 09, 2012 (BUSINESS WIRE) &#8212; Stealth Peptides Inc. (Stealth), a  privately held biopharmaceutical company developing innovative therapies  for diseases with unmet medical needs, announced today the results from  three Phase I <strong>clinical trials</strong> of <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/stealth-peptides-inc-reports-results-from-phase-i-clinical-drug-interaction-studies-with-bendavia-2012-04-09%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjABOAFA1vuL_ARIAVAAWABiBWVuLVVT&amp;cd=NTONxdq1Qm0&amp;usg=AFQjCNG3UZsf9KeJ8v7B1CE5m8Ggk3KM1w" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/stealth-peptides-inc-reports-results-from-phase-i-clinical-drug-interaction-studies-with-bendavia-2012-04-09&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/recurrent-prostate-cancer-treatment-research-indicates-new-phc-dietary-supplement-may-help-2012-04-09&amp;ct=ga&amp;cad=CAcQAhgAIAAoATACOAJA1vuL_ARIAVAAWABiBWVuLVVT&amp;cd=NTONxdq1Qm0&amp;usg=AFQjCNHeMCq0tV-tn4EO-UblGROQaj-umg" style="color: #1111cc" target="_blank">Recurrent Prostate Cancer Treatment: <strong>Research</strong> Indicates New PHC Dietary <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
LOS ANGELES, April 9, 2012 /PRNewswire via COMTEX/ &#8212; Preliminary findings from an FDA-approved <strong>clinical trial</strong>  indicate that the experimental dietary supplement Prostate Health  Cocktail (PHC®) may arrest and in some cases lower rising PSA (Prostate <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/recurrent-prostate-cancer-treatment-research-indicates-new-phc-dietary-supplement-may-help-2012-04-09%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjACOAJA1vuL_ARIAVAAWABiBWVuLVVT&amp;cd=NTONxdq1Qm0&amp;usg=AFQjCNHciGBF4roRgB4B7X_-A7TB6ZAcSw" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/recurrent-prostate-cancer-treatment-research-indicates-new-phc-dietary-supplement-may-help-2012-04-09&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px">
<table border="0" cellpadding="0" cellspacing="0" width="100%">
<tr>
<td valign="top"><a href="http://www.google.com/url?sa=X&amp;q=http://www.prweb.com/releases/2012/4/prweb9349355.htm&amp;ct=ga&amp;cad=CAcQAhgAIAAoATADOANA1vuL_ARIAVAAWABiBWVuLVVT&amp;cd=NTONxdq1Qm0&amp;usg=AFQjCNEkCIVcFLascytO0WS8mMv9UGFufg" style="color: #1111cc" target="_blank">Achieve <strong>Clinical Research</strong> Is Conducting New Rheumatoid Arthritis Trials in <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">PR Web (press release)</a><br />
Achieve <strong>Clinical Research</strong>, located in Birmingham, AL, has started enrolling participants for a new Rheumatoid Arthritis <strong>clinical trial</strong>. The study is open to adults ages 18 - 75 who have been diagnosed with Rheumatoid Arthritis.<br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.prweb.com/releases/2012/4/prweb9349355.htm%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjADOANA1vuL_ARIAVAAWABiBWVuLVVT&amp;cd=NTONxdq1Qm0&amp;usg=AFQjCNGWUdDDRv5IDnEV9_gw9PjFLLhuaA" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.prweb.com/releases/2012/4/prweb9349355.htm&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
<td align="center" valign="top" width="80"><a href="http://www.google.com/url?sa=X&amp;q=http://www.prweb.com/releases/2012/4/prweb9349355.htm&amp;ct=ga&amp;cad=CAcQAhgAIAAoAjADOANA1vuL_ARIAVAAWABiBWVuLVVT&amp;cd=NTONxdq1Qm0&amp;usg=AFQjCNEkCIVcFLascytO0WS8mMv9UGFufg" target="_blank"><img height="52" border="0" width="80" /></a><font size="-2"><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://www.prweb.com/releases/2012/4/prweb9349355.htm&amp;ct=ga&amp;cad=CAcQAhgAIAAoAzADOANA1vuL_ARIAVAAWABiBWVuLVVT&amp;cd=NTONxdq1Qm0&amp;usg=AFQjCNEkCIVcFLascytO0WS8mMv9UGFufg" target="_blank">PR Web (press release)</a></font></td>
</tr>
</table>
</td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/synergy-pharmaceuticals-achieves-halfway-mark-in-enrollment-on-plecanatide-phase-iiiii-trial-in-chronic-idiopathic-constipation-2012-04-09&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAEOARA1vuL_ARIAVAAWABiBWVuLVVT&amp;cd=NTONxdq1Qm0&amp;usg=AFQjCNGX1vwb0E1xIBmJsrRm3dJ0Q-u8qA" style="color: #1111cc" target="_blank">Synergy Pharmaceuticals Achieves Halfway Mark in Enrollment on Plecanatide <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
&#8220;We  are pleased with the vigorous pace of enrollment in this ongoing trial  and the overall enthusiasm from the more than 100 clinical sites  currently engaged in this <strong>clinical trial</strong>,&#8221; said Gary S. Jacob, Ph.D, President and Chief Executive Officer of <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/synergy-pharmaceuticals-achieves-halfway-mark-in-enrollment-on-plecanatide-phase-iiiii-trial-in-chronic-idiopathic-constipation-2012-04-09%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAEOARA1vuL_ARIAVAAWABiBWVuLVVT&amp;cd=NTONxdq1Qm0&amp;usg=AFQjCNGTxWVJl9xAGELSanI5e8cMorHrKw" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/synergy-pharmaceuticals-achieves-halfway-mark-in-enrollment-on-plecanatide-phase-iiiii-trial-in-chronic-idiopathic-constipation-2012-04-09&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px">
<table border="0" cellpadding="0" cellspacing="0" width="100%">
<tr>
<td valign="top"><a href="http://www.google.com/url?sa=X&amp;q=http://www.zdnetasia.com/indian-clinical-research-firm-looks-to-fill-innovation-gap-62304417.htm&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAFOAVA1vuL_ARIAVAAWABiBWVuLVVT&amp;cd=NTONxdq1Qm0&amp;usg=AFQjCNE9WkQRbvbDRTf_5v-amww0XRWjSA" style="color: #1111cc" target="_blank">Indian <strong>clinical research</strong> firm looks to fill innovation gap</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">ZDNet Asia</a><br />
Today, the Mumbai-headquartered <strong>clinical research</strong>  organization (CRO) clocks revenue of about US$10 million and is  targeting to increase this number to US$19.3 million by 2014. The  company provides a range of services from new drug development to <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.zdnetasia.com/indian-clinical-research-firm-looks-to-fill-innovation-gap-62304417.htm%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAFOAVA1vuL_ARIAVAAWABiBWVuLVVT&amp;cd=NTONxdq1Qm0&amp;usg=AFQjCNHb8NTqTVH8ti2MKBrezAHw9wyndg" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.zdnetasia.com/indian-clinical-research-firm-looks-to-fill-innovation-gap-62304417.htm&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
<td align="center" valign="top" width="80"><a href="http://www.google.com/url?sa=X&amp;q=http://www.zdnetasia.com/indian-clinical-research-firm-looks-to-fill-innovation-gap-62304417.htm&amp;ct=ga&amp;cad=CAcQAhgAIAAoAjAFOAVA1vuL_ARIAVAAWABiBWVuLVVT&amp;cd=NTONxdq1Qm0&amp;usg=AFQjCNE9WkQRbvbDRTf_5v-amww0XRWjSA" target="_blank"><img height="80" border="0" width="64" /></a><font size="-2"><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://www.zdnetasia.com/indian-clinical-research-firm-looks-to-fill-innovation-gap-62304417.htm&amp;ct=ga&amp;cad=CAcQAhgAIAAoAzAFOAVA1vuL_ARIAVAAWABiBWVuLVVT&amp;cd=NTONxdq1Qm0&amp;usg=AFQjCNE9WkQRbvbDRTf_5v-amww0XRWjSA" target="_blank">ZDNet Asia</a></font></td>
</tr>
</table>
</td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/adventrx-announces-establishment-of-regulatory-advisory-board-2012-04-09&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAGOAZA1vuL_ARIAVAAWABiBWVuLVVT&amp;cd=NTONxdq1Qm0&amp;usg=AFQjCNHHvBs1RkOowNqJyzx2u1hNs1d0Yw" style="color: #1111cc" target="_blank">ADVENTRX Announces Establishment of Regulatory Advisory Board</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
We look forward to advancing ANX-188 into a phase 3 <strong>clinical trial</strong>  later this year, and bringing the hope of a new therapy for sickle cell  patients one step closer to fruition.&#8221; In his practice at Hyman, Phelps  &amp; McNamara, PC, Mr. Sasinowski assists <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/adventrx-announces-establishment-of-regulatory-advisory-board-2012-04-09%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAGOAZA1vuL_ARIAVAAWABiBWVuLVVT&amp;cd=NTONxdq1Qm0&amp;usg=AFQjCNGlsUxENWGydK--JHUvTNIf2i81ag" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/adventrx-announces-establishment-of-regulatory-advisory-board-2012-04-09&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/musclepharm-announces-peer-reviewed-publication-showing-positive-clinical-study-results-of-pre-workout-supplement-assaulttm-2012-04-09&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAHOAdA1vuL_ARIAVAAWABiBWVuLVVT&amp;cd=NTONxdq1Qm0&amp;usg=AFQjCNG8ZeiV4YsrZwqu84glYJej1RCGJw" style="color: #1111cc" target="_blank">MusclePharm Announces Peer-Reviewed Publication Showing Positive <strong>Clinical</strong> <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
&#8220;Our  findings suggest that Assault(TM) can provide athletes with an overall  better workout experience by prolonging exercise performance, reducing  fatigue and increasing energy-levels,&#8221; said Jordan R. Moon, Ph.D., lead  researcher of the <strong>clinical trial</strong> <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/musclepharm-announces-peer-reviewed-publication-showing-positive-clinical-study-results-of-pre-workout-supplement-assaulttm-2012-04-09%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAHOAdA1vuL_ARIAVAAWABiBWVuLVVT&amp;cd=NTONxdq1Qm0&amp;usg=AFQjCNGFK96QGu33gO3s8nkiAVlMtQD_Ag" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/musclepharm-announces-peer-reviewed-publication-showing-positive-clinical-study-results-of-pre-workout-supplement-assaulttm-2012-04-09&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.medpagetoday.com/Endocrinology/Diabetes/32079&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAIOAhA1vuL_ARIAVAAWABiBWVuLVVT&amp;cd=NTONxdq1Qm0&amp;usg=AFQjCNFC9k2ezx2viCPavRr-pcvim7ahlg" style="color: #1111cc" target="_blank"><strong>Clinical</strong> Notes: Insulin Analog Safe in Pregnancy</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MedPage Today</a><br />
A drug intended to boost production of dystrophin in patients with Duchenne muscular dystrophy actually did so in a small <strong>clinical trial</strong>, but no functional benefit was apparent, according to the drug&#8217;s manufacturer. The disease is caused by a variety <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.medpagetoday.com/Endocrinology/Diabetes/32079%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAIOAhA1vuL_ARIAVAAWABiBWVuLVVT&amp;cd=NTONxdq1Qm0&amp;usg=AFQjCNECmPo_8wMsw-YCLMFoYym6e0rT9A" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.medpagetoday.com/Endocrinology/Diabetes/32079&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px">
<table border="0" cellpadding="0" cellspacing="0" width="100%">
<tr>
<td valign="top"><a href="http://www.google.com/url?sa=X&amp;q=http://nextbigfuture.com/2012/04/targeted-nanoparticles-show-success-in.html&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAJOAlA1vuL_ARIAVAAWABiBWVuLVVT&amp;cd=NTONxdq1Qm0&amp;usg=AFQjCNG7HcvgZS_dpFY6J4ag0m34WQ5oKA" style="color: #1111cc" target="_blank">Targeted nanoparticles show success in <strong>clinical trials</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">Next Big Future</a><br />
The  nanoparticles feature a homing molecule that allows them to  specifically attack cancer cells, and are the first such targeted  particles to enter human <strong>clinical studies</strong>. Originally developed by researchers at MIT and Brigham and Women&#8217;s Hospital in <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://nextbigfuture.com/2012/04/targeted-nanoparticles-show-success-in.html%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAJOAlA1vuL_ARIAVAAWABiBWVuLVVT&amp;cd=NTONxdq1Qm0&amp;usg=AFQjCNE5D8H349BrlApge37v9PL_DT5UtQ" style="color: #228822" title="http://news.google.com/news/story?ncl=http://nextbigfuture.com/2012/04/targeted-nanoparticles-show-success-in.html&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
<td align="center" valign="top" width="80"><a href="http://www.google.com/url?sa=X&amp;q=http://nextbigfuture.com/2012/04/targeted-nanoparticles-show-success-in.html&amp;ct=ga&amp;cad=CAcQAhgAIAAoAjAJOAlA1vuL_ARIAVAAWABiBWVuLVVT&amp;cd=NTONxdq1Qm0&amp;usg=AFQjCNG7HcvgZS_dpFY6J4ag0m34WQ5oKA" target="_blank"><img height="80" border="0" width="80" /></a><font size="-2"><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://nextbigfuture.com/2012/04/targeted-nanoparticles-show-success-in.html&amp;ct=ga&amp;cad=CAcQAhgAIAAoAzAJOAlA1vuL_ARIAVAAWABiBWVuLVVT&amp;cd=NTONxdq1Qm0&amp;usg=AFQjCNG7HcvgZS_dpFY6J4ag0m34WQ5oKA" target="_blank">Next Big Future</a></font></td>
</tr>
</table>
</td>
</tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" width="600px">
<tr>
<td style="background-color: #ebeff9; padding: 4px 8px">
<table border="0" cellpadding="0" cellspacing="0" width="100%">
<tr>
<td><font size="-1"><strong>Web</strong></font></td>
<td align="right" width="70%"><font size="-1"></font></td>
</tr>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://venus.provocateuse.com/cialis-bph-clinical-trial.html&amp;ct=ga&amp;cad=CAcQAhgAIAEoATAKOABA1vuL_ARIAVgAYgVlbi1VUw&amp;cd=NTONxdq1Qm0&amp;usg=AFQjCNHoRe5IEGbPJZNvrR8at-pCOHZrxw" style="color: #1111cc" target="_blank">Cialis bph <strong>clinical trial</strong> # Cialis online no prescription overnight <strong>&#8230;</strong></a><br />
<font size="-1">brand and generic Viagra in england, Cialis bph <strong>clinical trial</strong>.<br />
<a href="http://www.google.com/url?sa=X&amp;q=http://venus.provocateuse.com/cialis-bph-clinical-trial.html&amp;ct=ga&amp;cad=CAcQAhgAIAEoBDAKOABA1vuL_ARIAVgAYgVlbi1VUw&amp;cd=NTONxdq1Qm0&amp;usg=AFQjCNHoRe5IEGbPJZNvrR8at-pCOHZrxw" style="color: #228822" title="http://venus.provocateuse.com/cialis-bph-clinical-trial.html" target="_blank">venus.provocateuse.com/cialis-<wbr></wbr>bph-clinical-trial.html</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://cirmresearch.blogspot.com/2012/04/uc-davis-clinical-trial-helps-bones.html&amp;ct=ga&amp;cad=CAcQAhgAIAEoATALOAFA1vuL_ARIAVgAYgVlbi1VUw&amp;cd=NTONxdq1Qm0&amp;usg=AFQjCNHgYUPWAfhDN4Z2ufgmWwkeRpSLGw" style="color: #1111cc" target="_blank">CIRM Stem Cell Research Updates: UC Davis <strong>clinical trial</strong> helps <strong>&#8230;</strong></a><br />
<font size="-1">Souza told the story of the <strong>clinical trial</strong> at UC Davis that returned strength to her arm at the CIRM governing board&#8217;s Spotlight on Disease seminar on March 21st <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://cirmresearch.blogspot.com/2012/04/uc-davis-clinical-trial-helps-bones.html&amp;ct=ga&amp;cad=CAcQAhgAIAEoBDALOAFA1vuL_ARIAVgAYgVlbi1VUw&amp;cd=NTONxdq1Qm0&amp;usg=AFQjCNHgYUPWAfhDN4Z2ufgmWwkeRpSLGw" style="color: #228822" title="http://cirmresearch.blogspot.com/2012/04/uc-davis-clinical-trial-helps-bones.html" target="_blank">cirmresearch.blogspot.com/&#8230;/<wbr></wbr>uc-davis-clinical-trial-helps-<wbr></wbr>bon&#8230;</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://coloradosprings.backpage.com/FocusGroups/paid-clinical-trial-volunteers-needed-95-250-per-day/3881386&amp;ct=ga&amp;cad=CAcQAhgAIAEoATAMOAJA1vuL_ARIAVgAYgVlbi1VUw&amp;cd=NTONxdq1Qm0&amp;usg=AFQjCNGlhBmcl0qpJ1ewmT8xkG2Q6ve-Jg" style="color: #1111cc" target="_blank">Paid <strong>Clinical Trial</strong> Volunteers Needed - $95 - $250 per day <strong>&#8230;</strong></a><br />
<font size="-1">Colorado Springs. Colorado Springs, Colorado. Paid <strong>Clinical Trial</strong> Volunteers Needed - $95 - $250 per day.<br />
<a href="http://www.google.com/url?sa=X&amp;q=http://coloradosprings.backpage.com/FocusGroups/paid-clinical-trial-volunteers-needed-95-250-per-day/3881386&amp;ct=ga&amp;cad=CAcQAhgAIAEoBDAMOAJA1vuL_ARIAVgAYgVlbi1VUw&amp;cd=NTONxdq1Qm0&amp;usg=AFQjCNGlhBmcl0qpJ1ewmT8xkG2Q6ve-Jg" style="color: #228822" title="http://coloradosprings.backpage.com/FocusGroups/paid-clinical-trial-volunteers-needed-95-250-per-day/3881386" target="_blank">coloradosprings.backpage.com/<wbr></wbr>FocusGroups/&#8230;/3881386</a></font></td>
</tr>
</table>
]]></content:encoded>
			<wfw:commentRss>http://societyofcollegemedicine.com/2012/04/09/news-we-are-currently-tracking-8/feed/</wfw:commentRss>
		</item>
		<item>
		<title>News we are Currently Tracking&#8230;</title>
		<link>http://societyofcollegemedicine.com/2012/03/15/news-we-are-currently-tracking-7/</link>
		<comments>http://societyofcollegemedicine.com/2012/03/15/news-we-are-currently-tracking-7/#comments</comments>
		<pubDate>Thu, 15 Mar 2012 19:48:51 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://societyofcollegemedicine.com/2012/03/15/news-we-are-currently-tracking-7/</guid>
		<description><![CDATA[




News









New Report Shows Illinois Clinical Trials Benefit State&#8217;s Health and Economy
MarketWatch (press release)
WASHINGTON, Mar 15, 2012 (BUSINESS WIRE) &#8212; Working in collaboration with Illinois&#8217; university medical schools, hospitals and clinical research centers, the nation&#8217;s biopharmaceutical research companies are conducting or have conducted since 1999 &#8230;
See all stories on this topic »


Almac&#8217;s Clinical Trial Workshop Series [...]]]></description>
			<content:encoded><![CDATA[<table border="0" cellpadding="0" cellspacing="0" width="600px">
<tr>
<td style="background-color: #ebeff9; padding: 4px 8px">
<table border="0" cellpadding="0" cellspacing="0" width="100%">
<tr>
<td><font size="-1"><strong>News</strong></font></td>
<td width="70%" align="right"><font size="-1"></font></td>
</tr>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/new-report-shows-illinois-clinical-trials-benefit-states-health-and-economy-2012-03-15&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAAOABA-ZuI-wRIAVAAWABiBWVuLVVT&amp;cd=G1dDRo3o3fY&amp;usg=AFQjCNEynNpzKgbm5gmDbi3ASPz1yB71pQ" style="color: #1111cc" target="_blank">New Report Shows Illinois <strong>Clinical Trials</strong> Benefit State&#8217;s Health and Economy</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
WASHINGTON, Mar 15, 2012 (BUSINESS WIRE) &#8212; Working in collaboration with Illinois&#8217; university medical schools, hospitals and <strong>clinical research</strong> centers, the nation&#8217;s biopharmaceutical research companies are conducting or have conducted since 1999 <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/new-report-shows-illinois-clinical-trials-benefit-states-health-and-economy-2012-03-15%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAAOABA-ZuI-wRIAVAAWABiBWVuLVVT&amp;cd=G1dDRo3o3fY&amp;usg=AFQjCNHXtYsOMfoPuQNhh79LTX9sbriKyw" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/new-report-shows-illinois-clinical-trials-benefit-states-health-and-economy-2012-03-15&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/almacs-clinical-trial-workshop-series-to-return-in-2012-2012-03-15&amp;ct=ga&amp;cad=CAcQAhgAIAAoATABOAFA-ZuI-wRIAVAAWABiBWVuLVVT&amp;cd=G1dDRo3o3fY&amp;usg=AFQjCNEh7yiPV-5Na56CXLrV-1PBme5t_g" style="color: #1111cc" target="_blank">Almac&#8217;s <strong>Clinical Trial</strong> Workshop Series to Return in 2012</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
CRAIGAVON,  Northern Ireland, Mar 15, 2012 (BUSINESS WIRE) &#8212; Almac will be hosting  a series of complementary &#8216;lunch and learn&#8217; style workshops across  Europe and the US this spring tailored towards <strong>clinical trial</strong> / outsourcing professionals from <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/almacs-clinical-trial-workshop-series-to-return-in-2012-2012-03-15%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjABOAFA-ZuI-wRIAVAAWABiBWVuLVVT&amp;cd=G1dDRo3o3fY&amp;usg=AFQjCNG5Ez6BzA6Gnq_izi6BCHc0aZDjaA" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/almacs-clinical-trial-workshop-series-to-return-in-2012-2012-03-15&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/completed-clinical-trial-further-indicates-cell-in-a-boxr-encapsulation-technology-has-the-potential-to-treat-a-wide-array-of-solid-tumors-2012-03-15&amp;ct=ga&amp;cad=CAcQAhgAIAAoATACOAJA-ZuI-wRIAVAAWABiBWVuLVVT&amp;cd=G1dDRo3o3fY&amp;usg=AFQjCNE1dg8jDqQLaat2ouipHboztWaYUQ" style="color: #1111cc" target="_blank">Completed <strong>Clinical Trial</strong> Further Indicates Cell-in-a-Box(R) Encapsulation <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
Although the original human <strong>clinical trials</strong>  were limited to pancreatic cancer tumors, later work showed the  Cell-in-a-Box(R)encapsulation technology has great potential for use in  other solid tumors. The work also pointed toward encapsulated cells <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/completed-clinical-trial-further-indicates-cell-in-a-boxr-encapsulation-technology-has-the-potential-to-treat-a-wide-array-of-solid-tumors-2012-03-15%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjACOAJA-ZuI-wRIAVAAWABiBWVuLVVT&amp;cd=G1dDRo3o3fY&amp;usg=AFQjCNFxCT6AWteWm2VpqPnmyUQcDpQDLA" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/completed-clinical-trial-further-indicates-cell-in-a-boxr-encapsulation-technology-has-the-potential-to-treat-a-wide-array-of-solid-tumors-2012-03-15&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px">
<table border="0" cellpadding="0" cellspacing="0" width="100%">
<tr>
<td valign="top"><a href="http://www.google.com/url?sa=X&amp;q=http://www.physorg.com/wire-news/93260760/ottawa-researchers-to-lead-world-first-clinical-trial-of-stem-ce.html&amp;ct=ga&amp;cad=CAcQAhgAIAAoATADOANA-ZuI-wRIAVAAWABiBWVuLVVT&amp;cd=G1dDRo3o3fY&amp;usg=AFQjCNFYKLruYnCsioVrt98bvVc4QIedhA" style="color: #1111cc" target="_blank">Ottawa researchers to lead world-first <strong>clinical trial</strong> of stem cell therapy for <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">PhysOrg.com (press release)</a><br />
Dr.  Lauralyn McIntyre of the Ottawa Hospital Research Institute and the  University of Ottawa has been awarded more than $400000 from the  Canadian Institutes of Health Research and the Stem Cell Network to lead  the first <strong>clinical trial</strong> in the world of a <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.physorg.com/wire-news/93260760/ottawa-researchers-to-lead-world-first-clinical-trial-of-stem-ce.html%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjADOANA-ZuI-wRIAVAAWABiBWVuLVVT&amp;cd=G1dDRo3o3fY&amp;usg=AFQjCNGbGI_5PDiUR4tlpLLNIdMcYCnTdA" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.physorg.com/wire-news/93260760/ottawa-researchers-to-lead-world-first-clinical-trial-of-stem-ce.html&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
<td valign="top" width="80" align="center"><a href="http://www.google.com/url?sa=X&amp;q=http://www.physorg.com/wire-news/93260760/ottawa-researchers-to-lead-world-first-clinical-trial-of-stem-ce.html&amp;ct=ga&amp;cad=CAcQAhgAIAAoAjADOANA-ZuI-wRIAVAAWABiBWVuLVVT&amp;cd=G1dDRo3o3fY&amp;usg=AFQjCNFYKLruYnCsioVrt98bvVc4QIedhA" target="_blank"><img border="0" height="63" width="80" /></a><font size="-2"><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://www.physorg.com/wire-news/93260760/ottawa-researchers-to-lead-world-first-clinical-trial-of-stem-ce.html&amp;ct=ga&amp;cad=CAcQAhgAIAAoAzADOANA-ZuI-wRIAVAAWABiBWVuLVVT&amp;cd=G1dDRo3o3fY&amp;usg=AFQjCNFYKLruYnCsioVrt98bvVc4QIedhA" target="_blank">PhysOrg.com (press release)</a></font></td>
</tr>
</table>
</td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.sunherald.com/2012/03/15/3819062/research-and-markets-nicotine.html&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAEOARA-ZuI-wRIAVAAWABiBWVuLVVT&amp;cd=G1dDRo3o3fY&amp;usg=AFQjCNENZqTJNALxGPOzroG9VfNCV2lWyg" style="color: #1111cc" target="_blank">Research and Markets: Nicotine Addiction Global <strong>Clinical Trials</strong> Review, H1, 2012</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">SunHerald.com</a><br />
DUBLIN &#8212; Dublin - Research and Markets (<a href="http://www.researchandmarkets.com/research/0d7f8f46/nicotine_addiction" target="_blank">http://www.<wbr></wbr>researchandmarkets.com/<wbr></wbr>research/0d7f8f46/nicotine_<wbr></wbr>addiction</a>) has announced the addition of GlobalData&#8217;s new report &#8220;Nicotine Addiction Global <strong>Clinical Trials</strong> Review, H1, 2012&#8243; to their offering.<br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.sunherald.com/2012/03/15/3819062/research-and-markets-nicotine.html%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAEOARA-ZuI-wRIAVAAWABiBWVuLVVT&amp;cd=G1dDRo3o3fY&amp;usg=AFQjCNGDP8TU9GYlsJtpdEzlwhbxDtSRag" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.sunherald.com/2012/03/15/3819062/research-and-markets-nicotine.html&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/datatrak-international-inc-announces-fourth-quarter-and-full-year-results-for-2011-2012-03-15&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAFOAVA-ZuI-wRIAVAAWABiBWVuLVVT&amp;cd=G1dDRo3o3fY&amp;usg=AFQjCNFURdnI0pU42KqB6hiFXcyy0qTufA" style="color: #1111cc" target="_blank">DATATRAK International, Inc. Announces Fourth Quarter and Full Year Results <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
CLEVELAND,  March 15, 2012 /PRNewswire via COMTEX/ &#8212; DATATRAK International, Inc.  (otcqx:DATA), a technology and services company focused on global  eClinical solutions for the <strong>clinical trials</strong> industry, today announced its operating results for the <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/datatrak-international-inc-announces-fourth-quarter-and-full-year-results-for-2011-2012-03-15%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAFOAVA-ZuI-wRIAVAAWABiBWVuLVVT&amp;cd=G1dDRo3o3fY&amp;usg=AFQjCNG9GH7R2LRNa3PVqVNs_YqOJiAPkQ" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/datatrak-international-inc-announces-fourth-quarter-and-full-year-results-for-2011-2012-03-15&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.msnbc.msn.com/id/46736871/ns/health-cancer/&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAGOAZA-ZuI-wRIAVAAWABiBWVuLVVT&amp;cd=G1dDRo3o3fY&amp;usg=AFQjCNGf4kYq36LR6bg5Nry6uCclQYLjPg" style="color: #1111cc" target="_blank">Endocyte jumps on plans for cancer drug candidate</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">msnbc.com</a><br />
NEW YORK — Shares of Endocyte Inc. skyrocketed Wednesday after the company said it is close to restarting a <strong>clinical trial</strong>  of an experimental cancer drug, as well as filing for conditional  marketing approval in Europe. Don&#8217;t miss these Health stories <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.msnbc.msn.com/id/46736871/ns/health-cancer/%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAGOAZA-ZuI-wRIAVAAWABiBWVuLVVT&amp;cd=G1dDRo3o3fY&amp;usg=AFQjCNER1YYRIS0ynqtAuevBxhotXbkGTg" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.msnbc.msn.com/id/46736871/ns/health-cancer/&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.fiercevaccines.com/story/hep-c-vaccine-heads-further-clinical-trials/2012-03-15&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAHOAdA-ZuI-wRIAVAAWABiBWVuLVVT&amp;cd=G1dDRo3o3fY&amp;usg=AFQjCNEaRWE9egLRt-0adeKGKMR382ieLg" style="color: #1111cc" target="_blank">Hep C vaccine heads into further <strong>clinical trials</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">FierceVaccines</a><br />
Okairos, a spinout from Merck ($MRK), is starting a Phase I/II <strong>clinical trial</strong>  for its preventive hep C vaccine for people at risk of infection that  it says is the first multi-center, double-blinded, randomized,  placebo-controlled trial of a vaccine to <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.fiercevaccines.com/story/hep-c-vaccine-heads-further-clinical-trials/2012-03-15%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAHOAdA-ZuI-wRIAVAAWABiBWVuLVVT&amp;cd=G1dDRo3o3fY&amp;usg=AFQjCNEjJnBOLM41UCALDjY0F5dahj6qcg" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.fiercevaccines.com/story/hep-c-vaccine-heads-further-clinical-trials/2012-03-15&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/cytomedix-announces-publication-in-american-heart-journal-highlighting-positive-phase-i-clinical-data-using-ald-201-to-treat-ischemic-heart-failure-2012-03-15%3Freflink%3DMW_news_stmp&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAIOAhA-ZuI-wRIAVAAWABiBWVuLVVT&amp;cd=G1dDRo3o3fY&amp;usg=AFQjCNFqngzvYeXo05JnKCvf2ubH0SPyXw" style="color: #1111cc" target="_blank">Cytomedix Announces Publication in American Heart Journal Highlighting <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
&#8220;We are very encouraged by these positive data as they corroborate both the preclinical research and other <strong>clinical studies</strong> that suggest ALDH(br) cells specifically migrate to sites of ischemic damage and induce the formation of new blood vessels at <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/cytomedix-announces-publication-in-american-heart-journal-highlighting-positive-phase-i-clinical-data-using-ald-201-to-treat-ischemic-heart-failure-2012-03-15%253Freflink%253DMW_news_stmp%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAIOAhA-ZuI-wRIAVAAWABiBWVuLVVT&amp;cd=G1dDRo3o3fY&amp;usg=AFQjCNHZpbHUlY9PsW2bYYeGvbnI5Z3YmQ" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/cytomedix-announces-publication-in-american-heart-journal-highlighting-positive-phase-i-clinical-data-using-ald-201-to-treat-ischemic-heart-failure-2012-03-15%3Freflink%3DMW_news_stmp&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/oncolytics-biotech-inc-announces-2011-year-end-results-2012-03-15-7000&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAJOAlA-ZuI-wRIAVAAWABiBWVuLVVT&amp;cd=G1dDRo3o3fY&amp;usg=AFQjCNGR4q28Rltg4QIni7A9xwJ6gYd87g" style="color: #1111cc" target="_blank">Oncolytics Biotech® Inc. Announces 2011 Year End Results</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
&#8220;In the last year we made substantial progress as we announced positive <strong>clinical trial</strong> results and started <strong>clinical trials</strong>  in additional cancer indications while maintaining the strength of our  balance sheet,&#8221; said Dr. Brad Thompson, President and CEO <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/oncolytics-biotech-inc-announces-2011-year-end-results-2012-03-15-7000%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAJOAlA-ZuI-wRIAVAAWABiBWVuLVVT&amp;cd=G1dDRo3o3fY&amp;usg=AFQjCNEsUOd6G0vxSi6xxutYttPsbM4BHQ" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/oncolytics-biotech-inc-announces-2011-year-end-results-2012-03-15-7000&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" width="600px">
<tr>
<td style="background-color: #ebeff9; padding: 4px 8px">
<table border="0" cellpadding="0" cellspacing="0" width="100%">
<tr>
<td><font size="-1"><strong>Blogs</strong></font></td>
<td width="70%" align="right"><font size="-1"></font></td>
</tr>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.scynexis.com/dndi-launches-phase-i-in%25E2%2580%2590human-clinical-trial-for-promising/&amp;ct=ga&amp;cad=CAcQAhgAIAIoATAKOABA-ZuI-wRIAVgAYgVlbi1VUw&amp;cd=G1dDRo3o3fY&amp;usg=AFQjCNG3o7yFt_s8qUt1XNWcd3Nj5DQ6YA" style="color: #1111cc" target="_blank">DNDi Launches Phase I In‐Human <strong>Clinical Trial</strong> for Promising <strong>&#8230;</strong></a><br />
<font size="-1"><font color="#777777">By gary</font><br />
commenced a Phase I <em>clinical trial</em>  in healthy adults in Paris, France, to determine the safety and  tolerability of a promising oral drug candidate Oxaborole SCYX-7158, to  treat human African trypanosomiasis (HAT, or sleeping sickness) for <strong>&#8230;</strong><br />
<font color="#228822">SCYNEXIS</font></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.almacgroup.com/2012/03/almac%25E2%2580%2599s-clinical-trial-workshop-series-to-return-in-2012&amp;ct=ga&amp;cad=CAcQAhgAIAIoATALOAFA-ZuI-wRIAVgAYgVlbi1VUw&amp;cd=G1dDRo3o3fY&amp;usg=AFQjCNEwiqYPrBW4dMci99Y2ok8n1TBa6A" style="color: #1111cc" target="_blank">Almac&#8217;s <strong>Clinical Trial</strong> Workshop Series to return in 2012</a><br />
<font size="-1"><font color="#777777">By Ciara Fox</font><br />
March 15, 2012. Almac&#8217;s <em>Clinical Trial</em>  Workshop Series to return in 2012. Almac will be hosting a series of  complementary &#8216;lunch and learn&#8217; style workshops across Europe and the US  this spring tailored towards <em>clinical trial</em> / outsourcing <strong>&#8230;</strong><br />
<font color="#228822">Almac Group</font></font></td>
</tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" width="600px">
<tr>
<td style="background-color: #ebeff9; padding: 4px 8px">
<table border="0" cellpadding="0" cellspacing="0" width="100%">
<tr>
<td><font size="-1"><strong>Web</strong></font></td>
<td width="70%" align="right"><font size="-1"></font></td>
</tr>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.kgun9.com/news/local/142074873.html&amp;ct=ga&amp;cad=CAcQAhgAIAEoATAMOABA-ZuI-wRIAVgAYgVlbi1VUw&amp;cd=G1dDRo3o3fY&amp;usg=AFQjCNH8la6Cl20tqjs5fy9JmIN91aWFFQ" style="color: #1111cc" target="_blank"><strong>Clinical trial</strong> aims to improve HPV treatment - KGUN9.com</a><br />
<font size="-1">A <strong>clinical trial</strong> is going on across the country, including here in Southern Arizona, that could help thousands of women with HPV avoid surgery.<br />
<a href="http://www.google.com/url?sa=X&amp;q=http://www.kgun9.com/news/local/142074873.html&amp;ct=ga&amp;cad=CAcQAhgAIAEoBDAMOABA-ZuI-wRIAVgAYgVlbi1VUw&amp;cd=G1dDRo3o3fY&amp;usg=AFQjCNH8la6Cl20tqjs5fy9JmIN91aWFFQ" style="color: #228822" title="http://www.kgun9.com/news/local/142074873.html" target="_blank">www.kgun9.com/news/local/<wbr></wbr>142074873.html</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://jobs.newscientist.com/job/1401343662/international-clinical-trial-manager-europe/&amp;ct=ga&amp;cad=CAcQAhgAIAEoATANOAFA-ZuI-wRIAVgAYgVlbi1VUw&amp;cd=G1dDRo3o3fY&amp;usg=AFQjCNG8Vp1nBEm6KgHTetVxSF40SaMA9Q" style="color: #1111cc" target="_blank">International <strong>Clinical Trial</strong> Manager-Europe with SEC Recruitment <strong>&#8230;</strong></a><br />
<font size="-1">Employer:  SEC Recruitment, Location: Germany, ID: 1401343662, Hours: Full Time,  Contract type: Permanent, Date posted: 12 Mar 2012.<br />
<a href="http://www.google.com/url?sa=X&amp;q=http://jobs.newscientist.com/job/1401343662/international-clinical-trial-manager-europe/&amp;ct=ga&amp;cad=CAcQAhgAIAEoBDANOAFA-ZuI-wRIAVgAYgVlbi1VUw&amp;cd=G1dDRo3o3fY&amp;usg=AFQjCNG8Vp1nBEm6KgHTetVxSF40SaMA9Q" style="color: #228822" title="http://jobs.newscientist.com/job/1401343662/international-clinical-trial-manager-europe/" target="_blank">jobs.newscientist.com/&#8230;/<wbr></wbr>international-clinical-trial-<wbr></wbr>manager-eu&#8230;</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.bioportfolio.com/news/article/982338/New-Report-Shows-Illinois-Clinical-Trials-Benefit-State-s-Health-And-Economy.html&amp;ct=ga&amp;cad=CAcQAhgAIAEoATAOOAJA-ZuI-wRIAVgAYgVlbi1VUw&amp;cd=G1dDRo3o3fY&amp;usg=AFQjCNEI-wtO9SdUBPV06_LraogJi34DyA" style="color: #1111cc" target="_blank">New Report Shows Illinois <strong>Clinical Trials</strong> Benefit <strong>&#8230;</strong> - BioPortfolio</a><br />
<font size="-1">From BioPortfolio: Working in collaboration with Illinoisâ ™ university medical schools, hospitals and <strong>clinical</strong> research centers, the nationâ ™s <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://www.bioportfolio.com/news/article/982338/New-Report-Shows-Illinois-Clinical-Trials-Benefit-State-s-Health-And-Economy.html&amp;ct=ga&amp;cad=CAcQAhgAIAEoBDAOOAJA-ZuI-wRIAVgAYgVlbi1VUw&amp;cd=G1dDRo3o3fY&amp;usg=AFQjCNEI-wtO9SdUBPV06_LraogJi34DyA" style="color: #228822" title="http://www.bioportfolio.com/news/article/982338/New-Report-Shows-Illinois-Clinical-Trials-Benefit-State-s-Health-And-Economy.html" target="_blank">www.bioportfolio.com/&#8230;/New-<wbr></wbr>Report-Shows-Illinois-<wbr></wbr>Clinical-&#8230;</a></font></td>
</tr>
</table>
]]></content:encoded>
			<wfw:commentRss>http://societyofcollegemedicine.com/2012/03/15/news-we-are-currently-tracking-7/feed/</wfw:commentRss>
		</item>
		<item>
		<title>News we are Currently Tracking&#8230;</title>
		<link>http://societyofcollegemedicine.com/2012/03/14/news-we-are-currently-tracking-6/</link>
		<comments>http://societyofcollegemedicine.com/2012/03/14/news-we-are-currently-tracking-6/#comments</comments>
		<pubDate>Wed, 14 Mar 2012 15:06:09 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://societyofcollegemedicine.com/2012/03/14/news-we-are-currently-tracking-6/</guid>
		<description><![CDATA[




News









MolecularHealth Names Drug Safety and Personalized Medicine Expert Lawrence J &#8230;
MarketWatch (press release)
He was also a faculty member at the University of Massachusetts Medical Center and the Massachusetts College of Pharmacy. Dr. Lesko is a Fellow of the American College of Clinical Pharmacology, the American Association of Pharmaceutical Sciences and &#8230;
See all stories on this [...]]]></description>
			<content:encoded><![CDATA[<table border="0" cellpadding="0" cellspacing="0" width="600px">
<tr>
<td style="background-color: #ebeff9; padding: 4px 8px">
<table border="0" cellpadding="0" cellspacing="0" width="100%">
<tr>
<td><font size="-1"><strong>News</strong></font></td>
<td width="70%" align="right"><font size="-1"></font></td>
</tr>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/molecularhealth-names-drug-safety-and-personalized-medicine-expert-lawrence-j-lesko-as-scientific-advisor-2012-03-14&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAAOABAnN2C-wRIAVAAWABiBWVuLVVT&amp;cd=Rj-BNfQqZec&amp;usg=AFQjCNF95LsPicH-lADwkThcO9LT965YbA" style="color: #1111cc" target="_blank">MolecularHealth Names Drug Safety and Personalized <strong>Medicine</strong> Expert Lawrence J <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
He was also a faculty member at the University of Massachusetts <strong>Medical</strong> Center and the Massachusetts <strong>College</strong> of Pharmacy. Dr. Lesko is a Fellow of the American <strong>College</strong> of Clinical Pharmacology, the American Association of Pharmaceutical <strong>Sciences</strong> and <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/molecularhealth-names-drug-safety-and-personalized-medicine-expert-lawrence-j-lesko-as-scientific-advisor-2012-03-14%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAAOABAnN2C-wRIAVAAWABiBWVuLVVT&amp;cd=Rj-BNfQqZec&amp;usg=AFQjCNHSvSyH7amcyXCkj__nFuMwMiTAkA" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/molecularhealth-names-drug-safety-and-personalized-medicine-expert-lawrence-j-lesko-as-scientific-advisor-2012-03-14&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px">
<table border="0" cellpadding="0" cellspacing="0" width="100%">
<tr>
<td valign="top"><a href="http://www.google.com/url?sa=X&amp;q=http://www.bradenton.com/2012/03/14/3937317/local-medical-companies-and-schools.html&amp;ct=ga&amp;cad=CAcQAhgAIAAoATABOAFAnN2C-wRIAVAAWABiBWVuLVVT&amp;cd=Rj-BNfQqZec&amp;usg=AFQjCNGC75k59XuTRnyFSP2lPBUUyQ7s9A" style="color: #1111cc" target="_blank">Local <strong>medical</strong> companies and schools sponsor new exhibit at GWIZ <strong>Science</strong> Center <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">Bradenton Herald</a><br />
Meduzone consists of a career zone, interactive zone, operation simulation area, 3D learning zone, <strong>medical</strong> artifacts and a computer quiz area. Several local <strong>medical</strong> companies and <strong>colleges</strong> collaborated and sponsored the exhibit. The Manatee and Sarasota <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.bradenton.com/2012/03/14/3937317/local-medical-companies-and-schools.html%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjABOAFAnN2C-wRIAVAAWABiBWVuLVVT&amp;cd=Rj-BNfQqZec&amp;usg=AFQjCNGZXAc6sA6dp5AXUxxOqJgUFCcvvA" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.bradenton.com/2012/03/14/3937317/local-medical-companies-and-schools.html&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
<td valign="top" width="80" align="center"><a href="http://www.google.com/url?sa=X&amp;q=http://www.bradenton.com/2012/03/14/3937317/local-medical-companies-and-schools.html&amp;ct=ga&amp;cad=CAcQAhgAIAAoAjABOAFAnN2C-wRIAVAAWABiBWVuLVVT&amp;cd=Rj-BNfQqZec&amp;usg=AFQjCNGC75k59XuTRnyFSP2lPBUUyQ7s9A" target="_blank"><img border="0" height="60" width="80" /></a><font size="-2"><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://www.bradenton.com/2012/03/14/3937317/local-medical-companies-and-schools.html&amp;ct=ga&amp;cad=CAcQAhgAIAAoAzABOAFAnN2C-wRIAVAAWABiBWVuLVVT&amp;cd=Rj-BNfQqZec&amp;usg=AFQjCNGC75k59XuTRnyFSP2lPBUUyQ7s9A" target="_blank">Bradenton Herald</a></font></td>
</tr>
</table>
</td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.freep.com/article/20120314/NEWS06/203140381/Michigan-teen-s-breast-cancer-research-nets-him-36-100-000-1st-place-science-prize&amp;ct=ga&amp;cad=CAcQAhgAIAAoATACOAJAnN2C-wRIAVAAWABiBWVuLVVT&amp;cd=Rj-BNfQqZec&amp;usg=AFQjCNHOWcMTFIEDshgHWWzXaGEXQIHM6w" style="color: #1111cc" target="_blank">Michigan teen&#8217;s breast cancer research nets him $100000 1st-place <strong>science</strong> prize</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">Detroit Free Press</a><br />
By  Todd Spangler On Tuesday night, Nithin, a 17-year-old senior at Port  Huron Northern High School, won the $100000 first prize in the Intel <strong>Science</strong> Talent Search, the first Michigander to do so in the 70-year history of the competition.<br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.freep.com/article/20120314/NEWS06/203140381/Michigan-teen-s-breast-cancer-research-nets-him-36-100-000-1st-place-science-prize%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjACOAJAnN2C-wRIAVAAWABiBWVuLVVT&amp;cd=Rj-BNfQqZec&amp;usg=AFQjCNHpYQAvmGtvo2Lp4M_zOgaU6ZY57g" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.freep.com/article/20120314/NEWS06/203140381/Michigan-teen-s-breast-cancer-research-nets-him-36-100-000-1st-place-science-prize&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/media-advisory-2012-canada-gairdner-awards-to-be-unveiled-march-21-2012-03-14&amp;ct=ga&amp;cad=CAcQAhgAIAAoATADOANAnN2C-wRIAVAAWABiBWVuLVVT&amp;cd=Rj-BNfQqZec&amp;usg=AFQjCNFdl-NDfynDZ-MsKyUnqPb8JmEs7Q" style="color: #1111cc" target="_blank">Media Advisory - 2012 Canada Gairdner Awards to be Unveiled March 21</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
A source of national pride, the Awards are a major indicator of leading <strong>scientific</strong> discovery. Over the past 10 years, 18 of 27 Nobel Prize in <strong>Medicine</strong> winners had previously received a Canada Gairdner Award. In fact, one in four of all Canada Gairdner <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/media-advisory-2012-canada-gairdner-awards-to-be-unveiled-march-21-2012-03-14%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjADOANAnN2C-wRIAVAAWABiBWVuLVVT&amp;cd=Rj-BNfQqZec&amp;usg=AFQjCNGd59knwyhH92tAPmAoQUYZd8oCtg" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/media-advisory-2012-canada-gairdner-awards-to-be-unveiled-march-21-2012-03-14&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.newswise.com/articles/columbia-and-weill-cornell-join-national-effort-to-spur-clinical-trials-in-the-neurosciences&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAEOARAnN2C-wRIAVAAWABiBWVuLVVT&amp;cd=Rj-BNfQqZec&amp;usg=AFQjCNEiOlQuzT3X2LW4c3PPoTJCh196lw" style="color: #1111cc" target="_blank">Columbia and Weill Cornell Join National Effort to Spur Clinical Trials in the <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">Newswise (press release)</a><br />
Newswise — The National Institute for Neurological Disorders and Stroke (NINDS) has selected Columbia University <strong>College</strong> of Physicians and Surgeons and Weill Cornell <strong>Medical College</strong> to participate in a new national effort to accelerate the development <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.newswise.com/articles/columbia-and-weill-cornell-join-national-effort-to-spur-clinical-trials-in-the-neurosciences%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAEOARAnN2C-wRIAVAAWABiBWVuLVVT&amp;cd=Rj-BNfQqZec&amp;usg=AFQjCNGmb38JddfqybgrBr3KVXCaKvoN1A" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.newswise.com/articles/columbia-and-weill-cornell-join-national-effort-to-spur-clinical-trials-in-the-neurosciences&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.kansascity.com/2012/03/14/3490083/joco-research-triangle-at-last.html&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAFOAVAnN2C-wRIAVAAWABiBWVuLVVT&amp;cd=Rj-BNfQqZec&amp;usg=AFQjCNELK78hpv0kvSgkHLATZTEnsi5FyA" style="color: #1111cc" target="_blank">Joco Research Triangle at last is a dream come true</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">Kansas City Star</a><br />
The University of Kansas wanted more classroom space to expand business, engineering, <strong>science</strong> and technology programs for undergraduates and graduates on its Edwards campus in Overland Park. KU&#8217;s School of <strong>Medicine</strong> needed a cozy spot to test drugs and <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.kansascity.com/2012/03/14/3490083/joco-research-triangle-at-last.html%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAFOAVAnN2C-wRIAVAAWABiBWVuLVVT&amp;cd=Rj-BNfQqZec&amp;usg=AFQjCNFT0mLdfc6CM0ToWZ6jltSPimucVQ" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.kansascity.com/2012/03/14/3490083/joco-research-triangle-at-last.html&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.browndailyherald.com/med-school-rankings-rise-in-primary-care-fall-in-research-1.2715187&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAGOAZAnN2C-wRIAVAAWABiBWVuLVVT&amp;cd=Rj-BNfQqZec&amp;usg=AFQjCNEXQt2stD4wq-Rhv6fgW54r2I_03Q" style="color: #1111cc" target="_blank">Med School rankings rise in primary care, fall in research</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">The Brown Daily Herald</a><br />
The report released rankings for graduate programs in computer <strong>science</strong>, engineering, humanities, <strong>medical</strong> education and the <strong>sciences</strong>. <strong>Medical</strong> schools are ranked in two main categories — expertise in primary care for patients and research.<br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.browndailyherald.com/med-school-rankings-rise-in-primary-care-fall-in-research-1.2715187%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAGOAZAnN2C-wRIAVAAWABiBWVuLVVT&amp;cd=Rj-BNfQqZec&amp;usg=AFQjCNEBYoqMzDAH-_oTS5_-4ZIYS4mqUA" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.browndailyherald.com/med-school-rankings-rise-in-primary-care-fall-in-research-1.2715187&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.charlotteobserver.com/2012/03/14/3083755/south-meck-to-launch-new-medical.html&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAHOAdAnN2C-wRIAVAAWABiBWVuLVVT&amp;cd=Rj-BNfQqZec&amp;usg=AFQjCNEV94zKgOU0NQZU0Ds7rucC2T0STg" style="color: #1111cc" target="_blank">South Meck to launch new <strong>medical</strong> training</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">Charlotte Observer</a><br />
By Caroline McMillan A new high school biomedical <strong>science</strong> program offered through &#8220;Project Lead the Way&#8221; will introduce students to human <strong>medicine</strong>, physiology, genetics, microbiology and public health. South Mecklenburg High School&#8217;s new biomedical <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.charlotteobserver.com/2012/03/14/3083755/south-meck-to-launch-new-medical.html%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAHOAdAnN2C-wRIAVAAWABiBWVuLVVT&amp;cd=Rj-BNfQqZec&amp;usg=AFQjCNElCmzlirE9nikgsKP9gZx47AaEjg" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.charlotteobserver.com/2012/03/14/3083755/south-meck-to-launch-new-medical.html&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://thechronicleherald.ca/business/73213-nova-scotias-immunovaccine-partners-us-college-addiction-research&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAIOAhAnN2C-wRIAVAAWABiBWVuLVVT&amp;cd=Rj-BNfQqZec&amp;usg=AFQjCNHVVuKCyyjnKsESq06eTXPUiqldrw" style="color: #1111cc" target="_blank">Nova Scotia&#8217;s Immunovaccine partners with US <strong>college</strong> in addiction research</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">TheChronicleHerald.ca</a><br />
A Nova Scotia biotechnology company has inked a deal with a prestigious American <strong>medical</strong> research <strong>college</strong>. Immunovaccine Inc. has partnered with Weill Cornell <strong>Medical College</strong> in New York City to bolster a promising vaccine for treating cocaine <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://thechronicleherald.ca/business/73213-nova-scotias-immunovaccine-partners-us-college-addiction-research%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAIOAhAnN2C-wRIAVAAWABiBWVuLVVT&amp;cd=Rj-BNfQqZec&amp;usg=AFQjCNGntxnY6KccS3RjI8bnimm18F_Hlg" style="color: #228822" title="http://news.google.com/news/story?ncl=http://thechronicleherald.ca/business/73213-nova-scotias-immunovaccine-partners-us-college-addiction-research&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/teenager-unlocks-potential-pathways-for-breast-cancer-treatments-wins-intel-science-talent-search-2012-03-13&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAJOAlAnN2C-wRIAVAAWABiBWVuLVVT&amp;cd=Rj-BNfQqZec&amp;usg=AFQjCNH72vsdQ2ryUbi0dryiKUux5mrfbA" style="color: #1111cc" target="_blank">Teenager Unlocks Potential Pathways for Breast Cancer Treatments, Wins Intel <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
&#8211;The Intel <strong>Science</strong> Talent Search, the nation&#8217;s oldest and most prestigious pre-<strong>college science</strong>  and math competition, recognizes 40 high school seniors who are poised  to be the next leaders in innovation and help solve some of the world&#8217;s  greatest <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/teenager-unlocks-potential-pathways-for-breast-cancer-treatments-wins-intel-science-talent-search-2012-03-13%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAJOAlAnN2C-wRIAVAAWABiBWVuLVVT&amp;cd=Rj-BNfQqZec&amp;usg=AFQjCNES-ZJSgrVCM4lEDmW5wda2uikCWQ" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/teenager-unlocks-potential-pathways-for-breast-cancer-treatments-wins-intel-science-talent-search-2012-03-13&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
</table>
]]></content:encoded>
			<wfw:commentRss>http://societyofcollegemedicine.com/2012/03/14/news-we-are-currently-tracking-6/feed/</wfw:commentRss>
		</item>
		<item>
		<title>News we are Currently Tracking&#8230;</title>
		<link>http://societyofcollegemedicine.com/2012/03/09/news-we-are-currently-tracking-5/</link>
		<comments>http://societyofcollegemedicine.com/2012/03/09/news-we-are-currently-tracking-5/#comments</comments>
		<pubDate>Fri, 09 Mar 2012 02:14:47 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://societyofcollegemedicine.com/2012/03/09/news-we-are-currently-tracking-5/</guid>
		<description><![CDATA[




News
9 new results for clinical trial








Interim Clinical Trial Results Confirm Safety of Renadyl(TM), a Probiotic &#8230;
MarketWatch (press release)
NEWTOWN  SQUARE, Pa., March 8, 2012 /PRNewswire via COMTEX/ &#8212; On the occasion  of World Kidney Day, Kibow Biotech, Inc. is pleased to announce that  interim data from an expanded clinical trial of Renadyl(TM) ( [...]]]></description>
			<content:encoded><![CDATA[<table border="0" cellpadding="0" cellspacing="0" width="600px">
<tr>
<td style="background-color: #ebeff9; padding: 4px 8px">
<table border="0" cellpadding="0" cellspacing="0" width="100%">
<tr>
<td><font size="-1"><strong>News</strong></font></td>
<td width="70%" align="right"><font size="-1"><strong>9</strong> new results for <strong>clinical trial</strong></font></td>
</tr>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/interim-clinical-trial-results-confirm-safety-of-renadyltm-a-probiotic-dietary-supplement-for-the-support-of-healthy-kidney-function-2012-03-08&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAAOABAv5rj-gRIAVAAWABiBWVuLVVT&amp;cd=x4bDaByUyMU&amp;usg=AFQjCNHQ2V7F20CFy-NwdpaqqX3xmKId_w" style="color: #1111cc" target="_blank">Interim <strong>Clinical Trial</strong> Results Confirm Safety of Renadyl(TM), a Probiotic <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
NEWTOWN  SQUARE, Pa., March 8, 2012 /PRNewswire via COMTEX/ &#8212; On the occasion  of World Kidney Day, Kibow Biotech, Inc. is pleased to announce that  interim data from an expanded <strong>clinical trial</strong> of Renadyl(TM) ( <a href="http://www.renadyl.com/" target="_blank">http://www.Renadyl.com</a> ) confirms the <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/interim-clinical-trial-results-confirm-safety-of-renadyltm-a-probiotic-dietary-supplement-for-the-support-of-healthy-kidney-function-2012-03-08%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAAOABAv5rj-gRIAVAAWABiBWVuLVVT&amp;cd=x4bDaByUyMU&amp;usg=AFQjCNEMEpksI8GrBuu2jw9Urs3NP8IQKg" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/interim-clinical-trial-results-confirm-safety-of-renadyltm-a-probiotic-dietary-supplement-for-the-support-of-healthy-kidney-function-2012-03-08&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.sacbee.com/2012/03/08/4321095/interim-clinical-trial-results.html&amp;ct=ga&amp;cad=CAcQAhgAIAAoATABOAFAv5rj-gRIAVAAWABiBWVuLVVT&amp;cd=x4bDaByUyMU&amp;usg=AFQjCNHhaR6Hm6gHv2D432hFa7MFE9UlTg" style="color: #1111cc" target="_blank">Interim <strong>Clinical Trial</strong> Results Confirm Safety of Renadyl™, a Probiotic <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">Sacramento Bee</a><br />
By  Kibow Biotech, Inc. NEWTOWN SQUARE, Pa., March 8, 2012 &#8212; /PRNewswire/  &#8212; On the occasion of World Kidney Day, Kibow Biotech, Inc. is pleased  to announce that interim data from an expanded <strong>clinical trial</strong> of Renadyl™ (<a href="http://www/" target="_blank">http://www</a>.<br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.sacbee.com/2012/03/08/4321095/interim-clinical-trial-results.html%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjABOAFAv5rj-gRIAVAAWABiBWVuLVVT&amp;cd=x4bDaByUyMU&amp;usg=AFQjCNEc8FOLWfv5lFY3Ad1LGqtZ4TjB8A" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.sacbee.com/2012/03/08/4321095/interim-clinical-trial-results.html&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/palatin-technologies-completes-enrollment-in-phase-2b-bremelanotide-female-sexual-dysfunction-trial-2012-03-08&amp;ct=ga&amp;cad=CAcQAhgAIAAoATACOAJAv5rj-gRIAVAAWABiBWVuLVVT&amp;cd=x4bDaByUyMU&amp;usg=AFQjCNGiwx6vGxaabU1ILp4O995Z9HQKLA" style="color: #1111cc" target="_blank">Palatin Technologies Completes Enrollment in Phase 2B Bremelanotide Female <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
CRANBURY,  NJ, March 8, 2012 /PRNewswire via COMTEX/ &#8212; Palatin Technologies, Inc.  (ASE:PTN) today announced it has completed enrollment in its Phase 2B <strong>clinical trial</strong> evaluating the efficacy and safety of bremelanotide for treatment of female sexual <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/palatin-technologies-completes-enrollment-in-phase-2b-bremelanotide-female-sexual-dysfunction-trial-2012-03-08%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjACOAJAv5rj-gRIAVAAWABiBWVuLVVT&amp;cd=x4bDaByUyMU&amp;usg=AFQjCNHHEUo218D51iEdKTiCfSlbDofb3g" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/palatin-technologies-completes-enrollment-in-phase-2b-bremelanotide-female-sexual-dysfunction-trial-2012-03-08&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.news-medical.net/news/20120308/MRF-clinical-trial-to-examine-antigen-specific-MS-therapy.aspx&amp;ct=ga&amp;cad=CAcQAhgAIAAoATADOANAv5rj-gRIAVAAWABiBWVuLVVT&amp;cd=x4bDaByUyMU&amp;usg=AFQjCNHIdu2R5Ezc_5beJPCWfPjeSpWxfA" style="color: #1111cc" target="_blank">MRF <strong>clinical trial</strong> to examine antigen-specific MS therapy</a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">News-Medical.net</a><br />
The Myelin Repair Foundation (MRF) announced today that its <strong>research</strong> might soon lead into a <strong>clinical</strong> proof-of-concept <strong>trial</strong> at the Department of Neuroimmunology and Multiple Sclerosis <strong>Research</strong> (nims), University Hospital Zürich, Switzerland, <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.news-medical.net/news/20120308/MRF-clinical-trial-to-examine-antigen-specific-MS-therapy.aspx%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjADOANAv5rj-gRIAVAAWABiBWVuLVVT&amp;cd=x4bDaByUyMU&amp;usg=AFQjCNE324mwVg69b50SsA_PZZxBXxJcqQ" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.news-medical.net/news/20120308/MRF-clinical-trial-to-examine-antigen-specific-MS-therapy.aspx&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/trianz-solutions-releases-a-white-paper-entitled-switching-edc-platforms-to-rescue-in-flight-clinical-trials-2012-03-08&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAEOARAv5rj-gRIAVAAWABiBWVuLVVT&amp;cd=x4bDaByUyMU&amp;usg=AFQjCNGeukUTqdKHT4Fjq0jhE4C2RAVkZA" style="color: #1111cc" target="_blank">Trianz Solutions Releases a White Paper Entitled &#8220;Switching EDC Platforms to <strong>&#8230;</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">MarketWatch (press release)</a><br />
HERNDON,  Va., Mar 08, 2012 (BUSINESS WIRE) &#8212; Trianz Solutions, a global  technology provider of innovative solutions in eClinical trials, today  released a white paper entitled &#8220;Switching EDC Platforms to Rescue  In-flight <strong>Clinical Trials</strong>.<br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/trianz-solutions-releases-a-white-paper-entitled-switching-edc-platforms-to-rescue-in-flight-clinical-trials-2012-03-08%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAEOARAv5rj-gRIAVAAWABiBWVuLVVT&amp;cd=x4bDaByUyMU&amp;usg=AFQjCNHU9_LAtttINmWM-Jfcxd1V6v3dPQ" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/trianz-solutions-releases-a-white-paper-entitled-switching-edc-platforms-to-rescue-in-flight-clinical-trials-2012-03-08&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.fosters.com/apps/pbcs.dll/article%3FAID%3D/20120308/GJCOMMUNITY03/703089821/-1/SANNEWS&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAFOAVAv5rj-gRIAVAAWABiBWVuLVVT&amp;cd=x4bDaByUyMU&amp;usg=AFQjCNHxqGGU2mh8uYacVhwfK5wUBBv13g" style="color: #1111cc" target="_blank">Local cancer center conducts <strong>clinical trials</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">Foster&#8217;s Daily Democrat</a><br />
SANFORD — Dr. Can Ilyas is spreading the word that <strong>clinical trials</strong> are often conducted at the Cancer Care Center of York County in South Sanford. Ilyas is the oncologist and <strong>clinical trials</strong> primary investigator at the center. <strong>Clinical trials</strong> at the <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.fosters.com/apps/pbcs.dll/article%253FAID%253D/20120308/GJCOMMUNITY03/703089821/-1/SANNEWS%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAFOAVAv5rj-gRIAVAAWABiBWVuLVVT&amp;cd=x4bDaByUyMU&amp;usg=AFQjCNEindlg63Cxw32mQcjeAVEStCyHzg" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.fosters.com/apps/pbcs.dll/article%3FAID%3D/20120308/GJCOMMUNITY03/703089821/-1/SANNEWS&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.pehub.com/139751/imperial-innovations-circassia-completes-clinical-trial/&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAGOAZAv5rj-gRIAVAAWABiBWVuLVVT&amp;cd=x4bDaByUyMU&amp;usg=AFQjCNGBKqJAhZqHSDQ51UMScwaYuEikPw" style="color: #1111cc" target="_blank">Imperial Innovations&#8217; Circassia Completes <strong>Clinical Trial</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">Private Equity Hub (press release)</a><br />
“Circassia  is one of our most advanced investments and following the £60m  fundraising we led last year, we are pleased to see its success in  another key <strong>clinical trial</strong>. It is a great demonstration of the value being created within our portfolio and the <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.pehub.com/139751/imperial-innovations-circassia-completes-clinical-trial/%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAGOAZAv5rj-gRIAVAAWABiBWVuLVVT&amp;cd=x4bDaByUyMU&amp;usg=AFQjCNHxFIhyBcYvkRCqk_kEEPpKNyishQ" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.pehub.com/139751/imperial-innovations-circassia-completes-clinical-trial/&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://newamericamedia.org/2012/03/pharma-trade-group-calls-for-more-minorities-in-clinical-trials.php&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAHOAdAv5rj-gRIAVAAWABiBWVuLVVT&amp;cd=x4bDaByUyMU&amp;usg=AFQjCNEgoroMBt4S0kfe0Oa0MSfLXFnVpw" style="color: #1111cc" target="_blank">Pharma Trade Group Calls for More Minorities in <strong>Clinical Trials</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">New America Media</a><br />
CHICAGO – Communities most impacted by diabetes, heart disease and cancer are also the least likely to be enrolled in <strong>clinical trials</strong>, making it difficult for the US pharmaceutical industry to develop effective drugs to treat them.<br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://newamericamedia.org/2012/03/pharma-trade-group-calls-for-more-minorities-in-clinical-trials.php%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAHOAdAv5rj-gRIAVAAWABiBWVuLVVT&amp;cd=x4bDaByUyMU&amp;usg=AFQjCNHDo7yDeclSnR9mhtD6FBVAVURw2Q" style="color: #228822" title="http://news.google.com/news/story?ncl=http://newamericamedia.org/2012/03/pharma-trade-group-calls-for-more-minorities-in-clinical-trials.php&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.fiercevaccines.com/story/navy-moves-dengue-fever-vaccine-clinical-trials/2012-03-08&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAIOAhAv5rj-gRIAVAAWABiBWVuLVVT&amp;cd=x4bDaByUyMU&amp;usg=AFQjCNEyIkwxHziaRZdUVk3BfH_eA2tTwg" style="color: #1111cc" target="_blank">Navy moves dengue fever vaccine into <strong>clinical trials</strong></a><br />
<font size="-1"><a style="text-decoration: none; color: #777777">FierceVaccines</a><br />
Join thousands of lab <strong>research</strong>  professionals who get FierceVaccines via weekly email. Sign up today!  Dengue fever is a tropical disease caused by a virus, and is sometimes  called breakbone fever because it can cause intense muscle and joint  pain, <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.fiercevaccines.com/story/navy-moves-dengue-fever-vaccine-clinical-trials/2012-03-08%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAIOAhAv5rj-gRIAVAAWABiBWVuLVVT&amp;cd=x4bDaByUyMU&amp;usg=AFQjCNFRFPZexpr4xxxx_cwSGeZ5H1uRzA" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.fiercevaccines.com/story/navy-moves-dengue-fever-vaccine-clinical-trials/2012-03-08&amp;hl=en&amp;geo=us" target="_blank">See all stories on this topic »</a></font></td>
</tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" width="600px">
<tr>
<td style="background-color: #ebeff9; padding: 4px 8px">
<table border="0" cellpadding="0" cellspacing="0" width="100%">
<tr>
<td><font size="-1"><strong>Blogs</strong></font></td>
<td width="70%" align="right"><font size="-1"><strong>1</strong> new result for <strong>clinical trial</strong></font></td>
</tr>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://health.universityofcalifornia.edu/2012/03/07/questions-about-clinical-research-ucsfs-hub-website-has-answers/&amp;ct=ga&amp;cad=CAcQAhgAIAIoATAJOABAv5rj-gRIAVgAYgVlbi1VUw&amp;cd=x4bDaByUyMU&amp;usg=AFQjCNFS3B3e5krmFZREJEsibMU3rVTpqQ" style="color: #1111cc" target="_blank">Questions about <strong>clinical</strong> research? UCSF&#8217;s HUB website has <strong>&#8230;</strong></a><br />
<font size="-1"><font color="#777777">By alecrosenberg</font><br />
When it comes to <em>clinical trials</em>,  many patients know little about what it means to participate.  Physicians and researchers who seek to advance medical treatment and who  hope to inform patients who have few other options about promising but <strong>&#8230;</strong><br />
<font color="#228822">UC Health</font></font></td>
</tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" width="600px">
<tr>
<td style="background-color: #ebeff9; padding: 4px 8px">
<table border="0" cellpadding="0" cellspacing="0" width="100%">
<tr>
<td><font size="-1"><strong>Web</strong></font></td>
<td width="70%" align="right"><font size="-1"><strong>3</strong> new results for <strong>clinical trial</strong></font></td>
</tr>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.bioportfolio.com/news/article/974451/Aslan-Pharma-Selects-Pharmanet-i3-As-Clinical-Trial-Partner.html&amp;ct=ga&amp;cad=CAcQAhgAIAEoATAKOABAv5rj-gRIAVgAYgVlbi1VUw&amp;cd=x4bDaByUyMU&amp;usg=AFQjCNHQxsfQJo4OugCTJqNRz5g2VxO-tA" style="color: #1111cc" target="_blank">Aslan Pharma Selects PharmaNet/i3 as <strong>Clinical Trial</strong> Partner <strong>&#8230;</strong></a><br />
<font size="-1">From BioPortfolio: Aslan Pharma, the Singapore in-licensing startup, selected PharmaNet/i3 to conduct Phase I and Phase II <strong>clinical trials</strong> for two of Aslan&#8217;s <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://www.bioportfolio.com/news/article/974451/Aslan-Pharma-Selects-Pharmanet-i3-As-Clinical-Trial-Partner.html&amp;ct=ga&amp;cad=CAcQAhgAIAEoBDAKOABAv5rj-gRIAVgAYgVlbi1VUw&amp;cd=x4bDaByUyMU&amp;usg=AFQjCNHQxsfQJo4OugCTJqNRz5g2VxO-tA" style="color: #228822" title="http://www.bioportfolio.com/news/article/974451/Aslan-Pharma-Selects-Pharmanet-i3-As-Clinical-Trial-Partner.html" target="_blank">www.bioportfolio.com/&#8230;/<wbr></wbr>Aslan-Pharma-Selects-<wbr></wbr>Pharmanet-i3-&#8230;</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.smartbrief.com/servlet/rdrc%3Fu%3D%252Fnews%252FstoryDetails.jsp%253Fissueid%253DF2F284C0-555F-4793-B3FC-CF9E29D51397%2526copyid%253D4CE26113-A1A1-469E-A017-E8067FA9575D%2526brief%253Dsnm%2526sb_code%253Drss%2526%2526campaign%253Drss%26i%3DF2F284C0-555F-4793-B3FC-CF9E29D51397&amp;ct=ga&amp;cad=CAcQAhgAIAEoATALOAFAv5rj-gRIAVgAYgVlbi1VUw&amp;cd=x4bDaByUyMU&amp;usg=AFQjCNG0fjh9UOnQgQZad1ZaBqhy3oYFvQ" style="color: #1111cc" target="_blank">FDA completes guidelines on continuing <strong>clinical trial</strong> reviews <strong>&#8230;</strong></a><br />
<font size="-1">The  FDA has issued final guidelines on performing continuing reviews to  ensure the safety of participants in medical device and drug <strong>trials</strong>. The guidance, based <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://www.smartbrief.com/servlet/rdrc%3Fu%3D%252Fnews%252FstoryDetails.jsp%253Fissueid%253DF2F284C0-555F-4793-B3FC-CF9E29D51397%2526copyid%253D4CE26113-A1A1-469E-A017-E8067FA9575D%2526brief%253Dsnm%2526sb_code%253Drss%2526%2526campaign%253Drss%26i%3DF2F284C0-555F-4793-B3FC-CF9E29D51397&amp;ct=ga&amp;cad=CAcQAhgAIAEoBDALOAFAv5rj-gRIAVgAYgVlbi1VUw&amp;cd=x4bDaByUyMU&amp;usg=AFQjCNG0fjh9UOnQgQZad1ZaBqhy3oYFvQ" style="color: #228822" title="http://www.smartbrief.com/servlet/rdrc?u=%2Fnews%2FstoryDetails.jsp%3Fissueid%3DF2F284C0-555F-4793-B3FC-CF9E29D51397%26copyid%3D4CE26113-A1A1-469E-A017-E8067FA9575D%26brief%3Dsnm%26sb_code%3Drss%26%26campaign%3Drss&amp;i=F2F284C0-555F-4793-B3FC-CF9E29D51397" target="_blank">www.smartbrief.com/servlet/<wbr></wbr>rdrc?u&#8230;555F&#8230;i&#8230;</a></font></td>
</tr>
<tr>
<td style="padding: 0px 8px 16px"><a href="http://www.google.com/url?sa=X&amp;q=http://www.fiercevaccines.com/story/cuban-hiv-vaccine-enter-clinical-trials/2012-03-07%3Futm_medium%3Drss%26utm_source%3Drss&amp;ct=ga&amp;cad=CAcQAhgAIAEoATAMOAJAv5rj-gRIAVgAYgVlbi1VUw&amp;cd=x4bDaByUyMU&amp;usg=AFQjCNFH2F3VStgbfOpJyGn3Xa6PehAVxg" style="color: #1111cc" target="_blank">Cuban HIV vaccine to enter <strong>clinical trials</strong> - FierceVaccines</a><br />
<font size="-1"><strong>Clinical trials</strong>  of a new recombinant HIV vaccine from Cuba are expected to begin soon,  according to Enrique Iglesias, head of the vaccine development team, <strong>&#8230;</strong><br />
<a href="http://www.google.com/url?sa=X&amp;q=http://www.fiercevaccines.com/story/cuban-hiv-vaccine-enter-clinical-trials/2012-03-07%3Futm_medium%3Drss%26utm_source%3Drss&amp;ct=ga&amp;cad=CAcQAhgAIAEoBDAMOAJAv5rj-gRIAVgAYgVlbi1VUw&amp;cd=x4bDaByUyMU&amp;usg=AFQjCNFH2F3VStgbfOpJyGn3Xa6PehAVxg" style="color: #228822" title="http://www.fiercevaccines.com/story/cuban-hiv-vaccine-enter-clinical-trials/2012-03-07?utm_medium=rss&amp;utm_source=rss" target="_blank">www.fiercevaccines.com/story/<wbr></wbr>cuban&#8230;/2012-03-07?&#8230;</a></font></td>
</tr>
</table>
]]></content:encoded>
			<wfw:commentRss>http://societyofcollegemedicine.com/2012/03/09/news-we-are-currently-tracking-5/feed/</wfw:commentRss>
		</item>
		<item>
		<title>News we are Currently Tracking&#8230;</title>
		<link>http://societyofcollegemedicine.com/2012/03/02/news-we-are-currently-tracking-4/</link>
		<comments>http://societyofcollegemedicine.com/2012/03/02/news-we-are-currently-tracking-4/#comments</comments>
		<pubDate>Fri, 02 Mar 2012 01:37:53 +0000</pubDate>
		<dc:creator>admin</dc:creator>
		
		<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://societyofcollegemedicine.com/2012/03/02/news-we-are-currently-tracking-4/</guid>
		<description><![CDATA[




News
9 new results for clinical trial





 


Premier Research Names Eeva-Kaarina Koskelo, PhD, eMBA Executive Director &#8230;
Sacramento Bee
She joins an accomplished pediatrics team in the United States and Europe that provides full-service clinical trial management and regulatory support for pediatric trials. &#8220;Throughout her career, Eeva-Kaarina has been a recognized leader in pediatric &#8230;
See all stories on this [...]]]></description>
			<content:encoded><![CDATA[<table border="0" width="600" cellPadding="0" cellSpacing="0">
<tr>
<td style="padding-right: 8px; padding-left: 8px; padding-bottom: 4px; padding-top: 4px; background-color: #ebeff9">
<table border="0" width="100%" cellPadding="0" cellSpacing="0">
<tr>
<td><font size="-1"><u></u><strong>News</strong><u></u></font></td>
<td width="70%" align="right"><font size="-1"><strong>9</strong> new results for <strong>clinical trial</strong></font></td>
</tr>
</table>
</td>
</tr>
<tr>
<td> </td>
</tr>
<tr>
<td style="padding-right: 8px; padding-left: 8px; padding-bottom: 16px; padding-top: 0px"><a target="_blank" href="http://www.google.com/url?sa=X&amp;q=http://www.sacbee.com/2012/03/01/4303012/premier-research-names-eeva-kaarina.html&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAAOABAsKS--gRIAVAAWABiBWVuLVVT&amp;cd=vpq-J3Bw8y4&amp;usg=AFQjCNFNeA_NZJ-uydMbd3Vchl1CNkuQ4w" style="color: #1111cc">Premier <strong>Research</strong> Names Eeva-Kaarina Koskelo, PhD, eMBA Executive Director <strong>&#8230;</strong></a><br />
<font size="-1"><a style="color: #777777; text-decoration: none">Sacramento Bee</a><br />
She joins an accomplished pediatrics team in the United States and Europe that provides full-service <strong>clinical trial</strong> management and regulatory support for pediatric trials. &#8220;Throughout her career, Eeva-Kaarina has been a recognized leader in pediatric <strong>&#8230;</strong><br />
<a target="_blank" href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.sacbee.com/2012/03/01/4303012/premier-research-names-eeva-kaarina.html%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAAOABAsKS--gRIAVAAWABiBWVuLVVT&amp;cd=vpq-J3Bw8y4&amp;usg=AFQjCNGOUJa46hoCWZtc4skwtBvMfJggrw" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.sacbee.com/2012/03/01/4303012/premier-research-names-eeva-kaarina.html&amp;hl=en&amp;geo=us">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding-right: 8px; padding-left: 8px; padding-bottom: 16px; padding-top: 0px"><a target="_blank" href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/senesco-adds-second-clinical-site-to-evaluate-sns01-t-in-multiple-myeloma-2012-03-01&amp;ct=ga&amp;cad=CAcQAhgAIAAoATABOAFAsKS--gRIAVAAWABiBWVuLVVT&amp;cd=vpq-J3Bw8y4&amp;usg=AFQjCNG_k0dL0UhtDZMnSYjnv-LDuM4BbQ" style="color: #1111cc">Senesco Adds Second <strong>Clinical</strong> Site to Evaluate SNS01-T in Multiple Myeloma</a><br />
<font size="-1"><a style="color: #777777; text-decoration: none">MarketWatch (press release)</a><br />
BRIDGEWATER, NJ, Mar 01, 2012 (BUSINESS WIRE) &#8212; Senesco Technologies, Inc. (&#8221;Senesco&#8221; or the &#8220;Company&#8221;) (ASE:SNT) today announced that it has received Institutional Review Board approval and has finalized a <strong>clinical trial</strong> research agreement with the <strong>&#8230;</strong><br />
<a target="_blank" href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/senesco-adds-second-clinical-site-to-evaluate-sns01-t-in-multiple-myeloma-2012-03-01%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjABOAFAsKS--gRIAVAAWABiBWVuLVVT&amp;cd=vpq-J3Bw8y4&amp;usg=AFQjCNGwZltzyOYGnNvOdtomzt2xFgcsvw" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/senesco-adds-second-clinical-site-to-evaluate-sns01-t-in-multiple-myeloma-2012-03-01&amp;hl=en&amp;geo=us">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding-right: 8px; padding-left: 8px; padding-bottom: 16px; padding-top: 0px"><a target="_blank" href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/trianz-solutions-announces-the-next-version-of-acceliant-eclinical-trial-suite-v64-2012-03-01&amp;ct=ga&amp;cad=CAcQAhgAIAAoATACOAJAsKS--gRIAVAAWABiBWVuLVVT&amp;cd=vpq-J3Bw8y4&amp;usg=AFQjCNEgEIu9yjTzFos6t9CJWOuqpWiywA" style="color: #1111cc">Trianz Solutions Announces the Next Version of Acceliant eClinical <strong>Trial</strong> Suite <strong>&#8230;</strong></a><br />
<font size="-1"><a style="color: #777777; text-decoration: none">MarketWatch (press release)</a><br />
HERNDON, Va., Mar 01, 2012 (BUSINESS WIRE) &#8212; Trianz Solutions, a global technology provider of innovative solutions in <strong>clinical trials</strong> announces the launch of Acceliant eClinical Suite-v6.4, the latest upgrade to their <strong>clinical trial</strong> solution.<br />
<a target="_blank" href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/trianz-solutions-announces-the-next-version-of-acceliant-eclinical-trial-suite-v64-2012-03-01%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjACOAJAsKS--gRIAVAAWABiBWVuLVVT&amp;cd=vpq-J3Bw8y4&amp;usg=AFQjCNEB0e2bBqWfbiQ3FoNQEcdrueewgg" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/trianz-solutions-announces-the-next-version-of-acceliant-eclinical-trial-suite-v64-2012-03-01&amp;hl=en&amp;geo=us">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding-right: 8px; padding-left: 8px; padding-bottom: 16px; padding-top: 0px"><a target="_blank" href="http://www.google.com/url?sa=X&amp;q=http://www.reuters.com/article/2012/02/29/idUS251947%2B29-Feb-2012%2BHUG20120229&amp;ct=ga&amp;cad=CAcQAhgAIAAoATADOANAsKS--gRIAVAAWABiBWVuLVVT&amp;cd=vpq-J3Bw8y4&amp;usg=AFQjCNHTjFHLHneaObio02HRR1Nlqxqeaw" style="color: #1111cc">Two Phase III <strong>studies</strong> of Novartis drug INC424 published in NEJM show <strong>&#8230;</strong></a><br />
<font size="-1"><a style="color: #777777; text-decoration: none">Reuters</a><br />
Novartis International AG / Two Phase III <strong>studies</strong> of Novartis drug INC424 published in NEJM show significant <strong>clinical</strong> benefit for patients with myelofibrosis . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the <strong>&#8230;</strong><br />
<a target="_blank" href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.reuters.com/article/2012/02/29/idUS251947%252B29-Feb-2012%252BHUG20120229%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjADOANAsKS--gRIAVAAWABiBWVuLVVT&amp;cd=vpq-J3Bw8y4&amp;usg=AFQjCNGwXRttkZoDdGjjzykWv1FRH2U43g" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.reuters.com/article/2012/02/29/idUS251947%2B29-Feb-2012%2BHUG20120229&amp;hl=en&amp;geo=us">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding-right: 8px; padding-left: 8px; padding-bottom: 16px; padding-top: 0px"><a target="_blank" href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/aastrom-biosciences-announces-initiation-of-patient-enrollment-in-revive-phase-3-clinical-trial-of-ixmyelocel-t-2012-02-29&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAEOARAsKS--gRIAVAAWABiBWVuLVVT&amp;cd=vpq-J3Bw8y4&amp;usg=AFQjCNFTYzB9gA3LagR63te2L3dt9xlDVQ" style="color: #1111cc">Aastrom Biosciences Announces Initiation of Patient Enrollment in REVIVE Phase <strong>&#8230;</strong></a><br />
<font size="-1"><a style="color: #777777; text-decoration: none">MarketWatch (press release)</a><br />
This REVIVE <strong>clinical trial</strong> is supported by an independent steering committee of renowned leaders in vascular medicine and <strong>clinical research</strong> who will provide independent oversight as well as medical and clinical guidance.<br />
<a target="_blank" href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/aastrom-biosciences-announces-initiation-of-patient-enrollment-in-revive-phase-3-clinical-trial-of-ixmyelocel-t-2012-02-29%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAEOARAsKS--gRIAVAAWABiBWVuLVVT&amp;cd=vpq-J3Bw8y4&amp;usg=AFQjCNHEetoDdO_DzqApLwTY7yumJ-ROpg" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/aastrom-biosciences-announces-initiation-of-patient-enrollment-in-revive-phase-3-clinical-trial-of-ixmyelocel-t-2012-02-29&amp;hl=en&amp;geo=us">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding-right: 8px; padding-left: 8px; padding-bottom: 16px; padding-top: 0px"><a target="_blank" href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/mednet-solutions-to-showcase-imednet-edc-at-the-2012-partnerships-in-clinical-trials-conference-2012-02-29&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAFOAVAsKS--gRIAVAAWABiBWVuLVVT&amp;cd=vpq-J3Bw8y4&amp;usg=AFQjCNETCrkzBJ8G6y1T1TClOvkSYh7lAA" style="color: #1111cc">MedNet Solutions to Showcase iMedNet EDC at the 2012 Partnerships in <strong>Clinical</strong> <strong>&#8230;</strong></a><br />
<font size="-1"><a style="color: #777777; text-decoration: none">MarketWatch (press release)</a><br />
iMedNet EDC is a groundbreaking technology platform that allows study sponsors and <strong>clinical research</strong> organizations (CROs) to significantly reduce research-related costs - including time, personnel and expenditures. iMedNet EDC allows non-technical <strong>&#8230;</strong><br />
<a target="_blank" href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/mednet-solutions-to-showcase-imednet-edc-at-the-2012-partnerships-in-clinical-trials-conference-2012-02-29%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAFOAVAsKS--gRIAVAAWABiBWVuLVVT&amp;cd=vpq-J3Bw8y4&amp;usg=AFQjCNGtx-Owp3OdC1KyqAQws6wFa3rV4A" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/mednet-solutions-to-showcase-imednet-edc-at-the-2012-partnerships-in-clinical-trials-conference-2012-02-29&amp;hl=en&amp;geo=us">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding-right: 8px; padding-left: 8px; padding-bottom: 16px; padding-top: 0px"><a target="_blank" href="http://www.google.com/url?sa=X&amp;q=http://online.wsj.com/article/BT-CO-20120229-714567.html&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAGOAZAsKS--gRIAVAAWABiBWVuLVVT&amp;cd=vpq-J3Bw8y4&amp;usg=AFQjCNHh15Nv_bgbSq8714HIyTd_PCZtHA" style="color: #1111cc">Merck Legal Settlement To Bolster <strong>Clinical</strong> Data Reporting</a><br />
<font size="-1"><a style="color: #777777; text-decoration: none">Wall Street Journal</a><br />
s (MRK) drug research arm to inform the company&#8217;s board of directors of delays in reporting <strong>clinical trial</strong> results. The settlement ends part of the litigation that followed the 2008 release of results of the &#8220;Enhance&#8221; <strong>clinical trial</strong> of Merck&#8217;s <strong>&#8230;</strong><br />
<a target="_blank" href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://online.wsj.com/article/BT-CO-20120229-714567.html%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAGOAZAsKS--gRIAVAAWABiBWVuLVVT&amp;cd=vpq-J3Bw8y4&amp;usg=AFQjCNEjZVdIwlrKUM8h7NakqfZ401Vi0g" style="color: #228822" title="http://news.google.com/news/story?ncl=http://online.wsj.com/article/BT-CO-20120229-714567.html&amp;hl=en&amp;geo=us">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding-right: 8px; padding-left: 8px; padding-bottom: 16px; padding-top: 0px"><a target="_blank" href="http://www.google.com/url?sa=X&amp;q=http://www.marketwatch.com/story/opexa-therapeutics-executes-strategic-service-agreement-with-pharmaceutical-research-associates-to-manage-clinical-trial-2012-02-29&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAHOAdAsKS--gRIAVAAWABiBWVuLVVT&amp;cd=vpq-J3Bw8y4&amp;usg=AFQjCNEM5ufZyPiUz2XzXoaJEBqRNOTu4g" style="color: #1111cc">Opexa Therapeutics Executes Strategic Service Agreement with Pharmaceutical <strong>&#8230;</strong></a><br />
<font size="-1"><a style="color: #777777; text-decoration: none">MarketWatch (press release)</a><br />
We are confident that this collaboration with PRA&#8217;s top-notch clinical management team will provide Opexa superior support to accumulate and report the data from this study in an efficient and cost effective manner. Our <strong>clinical trial</strong> plans are <strong>&#8230;</strong><br />
<a target="_blank" href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.marketwatch.com/story/opexa-therapeutics-executes-strategic-service-agreement-with-pharmaceutical-research-associates-to-manage-clinical-trial-2012-02-29%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAHOAdAsKS--gRIAVAAWABiBWVuLVVT&amp;cd=vpq-J3Bw8y4&amp;usg=AFQjCNEKM55r73I9i9JSsIRZYOj5F2V1hA" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.marketwatch.com/story/opexa-therapeutics-executes-strategic-service-agreement-with-pharmaceutical-research-associates-to-manage-clinical-trial-2012-02-29&amp;hl=en&amp;geo=us">See all stories on this topic »</a></font></td>
</tr>
<tr>
<td style="padding-right: 8px; padding-left: 8px; padding-bottom: 16px; padding-top: 0px"><a target="_blank" href="http://www.google.com/url?sa=X&amp;q=http://www.businesswire.com/news/home/20120301006071/en/Research-Markets-Post-Traumatic-Stress-Disorder-PTSD-Global&amp;ct=ga&amp;cad=CAcQAhgAIAAoATAIOAhAsKS--gRIAVAAWABiBWVuLVVT&amp;cd=vpq-J3Bw8y4&amp;usg=AFQjCNFxqYeE0YsSgyZJkiksUqt0vpSW9g" style="color: #1111cc"><strong>Research</strong> and Markets: Post-Traumatic Stress Disorder (PTSD) Global <strong>Clinical</strong> <strong>&#8230;</strong></a><br />
<font size="-1"><a style="color: #777777; text-decoration: none">Business Wire (press release)</a><br />
GlobalData&#8217;s <strong>clinical trial</strong> report, Post-Traumatic Stress Disorder (PTSD) Global <strong>Clinical Trials</strong> Review, H2, 2011&#8243; provides data on the Post-Traumatic Stress Disorder (PTSD) <strong>clinical trial</strong> scenario. This report provides elemental information and data <strong>&#8230;</strong><br />
<a target="_blank" href="http://www.google.com/url?sa=X&amp;q=http://news.google.com/news/story%3Fncl%3Dhttp://www.businesswire.com/news/home/20120301006071/en/Research-Markets-Post-Traumatic-Stress-Disorder-PTSD-Global%26hl%3Den%26geo%3Dus&amp;ct=ga&amp;cad=CAcQAhgAIAAoBjAIOAhAsKS--gRIAVAAWABiBWVuLVVT&amp;cd=vpq-J3Bw8y4&amp;usg=AFQjCNFcvWuYoK35x5yMLVYKryaLLCb_mA" style="color: #228822" title="http://news.google.com/news/story?ncl=http://www.businesswire.com/news/home/20120301006071/en/Research-Markets-Post-Traumatic-Stress-Disorder-PTSD-Global&amp;hl=en&amp;geo=us">See all stories on this topic »</a></font></td>
</tr>
</table>
<table border="0" width="600" cellPadding="0" cellSpacing="0">
<tr>
<td style="padding-right: 8px; padding-left: 8px; padding-bottom: 4px; padding-top: 4px; background-color: #ebeff9">
<table border="0" width="100%" cellPadding="0" cellSpacing="0">
<tr>
<td><font size="-1"><u></u><strong>Blogs</strong><u></u></font></td>
<td width="70%" align="right"><font size="-1"><strong>2</strong> new results for <strong>clinical trial</strong></font></td>
</tr>
</table>
</td>
</tr>
<tr>
<td> </td>
</tr>
<tr>
<td style="padding-right: 8px; padding-left: 8px; padding-bottom: 16px; padding-top: 0px"><a target="_blank" href="http://www.google.com/url?sa=X&amp;q=http://www.massdevice.com/news/weight-loss-gi-dynamics-us-clinical-trial-tap-year&amp;ct=ga&amp;cad=CAcQAhgAIAIoATAJOABAsKS--gRIAVgAYgVlbi1VUw&amp;cd=vpq-J3Bw8y4&amp;usg=AFQjCNF2yvXjcP6T3VMsKfHGRwzCyQg1Tw" style="color: #1111cc">Weight loss: GI Dynamics: U.S. <strong>clinical trial</strong> on tap for this year <strong>&#8230;</strong></a><br />
<font size="-1"><font color="#777777">By MassDevice staff</font><br />
In its first earnings release as a publicly traded company, GI Dynamics says it brought in $234000 last year, for a net loss of $26.4 million, and is negotiating the parameters of a U.S. <em>clinical trial</em> with the FDA for its EndoBarrier weight-loss and <strong>&#8230;</strong><br />
<font color="#228822">MassDevice - FDA and Medical&#8230;</font></font></td>
</tr>
<tr>
<td style="padding-right: 8px; padding-left: 8px; padding-bottom: 16px; padding-top: 0px"><a target="_blank" href="http://www.google.com/url?sa=X&amp;q=http://www.healthimaginghub.com/index.php%3Foption%3Dcom_content%26task%3Dview%26id%3D3662%26Itemid%3D126&amp;ct=ga&amp;cad=CAcQAhgAIAIoATAKOAFAsKS--gRIAVgAYgVlbi1VUw&amp;cd=vpq-J3Bw8y4&amp;usg=AFQjCNHfejj84AIE-i3gWQpVWSA-j3Tvzw" style="color: #1111cc">WorldCare <strong>Clinical</strong> Organizes Conference on Imaging in <strong>Trials</strong></a><br />
<font size="-1"><font color="#777777">By <a target="_blank" href="https://mail.google.com/mail/h/5nklyt1k0lp7/?&amp;v=b&amp;cs=wh&amp;to=info@healthimaginghub.com">info@healthimaginghub.com</a></font><br />
WorldCare Clinical, LLC (WCC) announced recently that it will organize a conference on “Imaging in <em>Clinical Trials</em> - Removing Bias and Increasing Precision and Accuracy”.<br />
<font color="#228822">Health Imaging Hub | All Countries News</font></font></td>
</tr>
</table>
<table border="0" width="600" cellPadding="0" cellSpacing="0">
<tr>
<td style="padding-right: 8px; padding-left: 8px; padding-bottom: 4px; padding-top: 4px; background-color: #ebeff9">
<table border="0" width="100%" cellPadding="0" cellSpacing="0">
<tr>
<td><font size="-1"><u></u><strong>Web</strong><u></u></font></td>
<td width="70%" align="right"><font size="-1"><strong>1</strong> new result for <strong>clinical trial</strong></font></td>
</tr>
</table>
</td>
</tr>
<tr>
<td> </td>
</tr>
<tr>
<td style="padding-right: 8px; padding-left: 8px; padding-bottom: 16px; padding-top: 0px"><a target="_blank" href="http://www.google.com/url?sa=X&amp;q=http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/News/Quintiles-Celebrates-30th-Anniversary-of-Providing/ArticleStandard/Article/detail/761996%3FcontextCategoryId%3D3300&amp;ct=ga&amp;cad=CAcQAhgAIAEoATALOABAsKS--gRIAVgAYgVlbi1VUw&amp;cd=vpq-J3Bw8y4&amp;usg=AFQjCNHW0B1WZRFsbYOCVQDmI_2JeYEGSg" style="color: #1111cc">Quintiles Celebrates 30th Anniversary of <strong>&#8230;</strong> - Applied <strong>Clinical Trials</strong></a><br />
<font size="-1">Developments, news and strategies for drug development specific to phase I through Phase III global <strong>clinical trial</strong> management, execution, project management <strong>&#8230;</strong><br />
<a target="_blank" href="http://www.google.com/url?sa=X&amp;q=http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/News/Quintiles-Celebrates-30th-Anniversary-of-Providing/ArticleStandard/Article/detail/761996%3FcontextCategoryId%3D3300&amp;ct=ga&amp;cad=CAcQAhgAIAEoBDALOABAsKS--gRIAVgAYgVlbi1VUw&amp;cd=vpq-J3Bw8y4&amp;usg=AFQjCNHW0B1WZRFsbYOCVQDmI_2JeYEGSg" style="color: #228822" title="http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/News/Quintiles-Celebrates-30th-Anniversary-of-Providing/ArticleStandard/Article/detail/761996?contextCategoryId=3300">www.<wbr></wbr>appliedclinicaltrialsonline.<wbr></wbr>com/&#8230;/News/&#8230;/761996?&#8230;</a></font></td>
</tr>
</table>
]]></content:encoded>
			<wfw:commentRss>http://societyofcollegemedicine.com/2012/03/02/news-we-are-currently-tracking-4/feed/</wfw:commentRss>
		</item>
	</channel>
</rss>

